

Deliverable 3.8

Implementation of Public Dialogues on Disruptive Technologies



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 741527.

Project Acronym	ORION
Project Title	Open Responsible research and Innovation to further Outstanding kNowledge
Grant Agreement no.	741527
Start date of the project	01/05/2017
End date of the project	30/09/2021
Work Package number	WP3
Deliverable Number	D3.8
Deliverable title	Public dialogues workshop on disruptive initiatives
Lead Beneficiary	Babraham Institute
Due date	M36
Date of delivery	21/12/2020
Nature	Report
Dissemination level	Public

DISCLAIMER

The information in this document is provided "as is", and no guarantee or warranty is given that the information is fit for any particular purpose. The document reflects only the authors' view. The ORION is not responsible for any use that may be made of the information it contains. The user uses the information at its sole risk and liability.

Version	Contributors	Comments
1.0	BI	First version
2.0	CRECIM, MDC, CEITEC	Corrections
3.0	BI	Extended version with all
		Ipsos Mori reports
4.0	BI, CRG	Shortened and final version





Contents

E	xecutive summary	3
	Introduction	
2.	Dialogue Design and Delivery Method	
	2.1. Overview and Timings	7
	2.2. Governance	8
	2.3. Planning and Design	10
	2.4. Recruitment of public participants	11
3.	Outputs	
	Babraham Institute (BI):	11
	Max Delbrück Center for Molecular Medicine (MDC):	
	The Central European Institute of Technology (CEITEC):	12
	Vetenskap & Allmänhet (VA):	
	3.2 'AEON Trajectories of Longevity' Science Art piece	
	3.3 Four stakeholder workshops	14
	3.4 Four reconvened events with the public	15
	3.5 Four findings' reports and one synthesis report	16
4.	Next steps	17
	4.1. Two scholarly articles	
	4.2 Dissemination article at a scientific magazine/journal	18
	4.3 Training materials	18
	4.4 Event to launch findings	18
	Evaluation Conclusions	20
	Part I: Reflection on the findings of ORION public dialogue on genome editing	20
	Part II: Why public dialogue and public engagement are part of open science	21
	Part III: How does this public dialogue contribute to open science institutionalisation in research performing organisations?	
Αı	nnexes: Ipsos Mori synthesis and country reports	23



Executive summary

As part of the Horizon 2020 funded ORION (Open Responsible research and Innovation to further Outstanding kNowledge) project, four life science and biomedical research organisations in Europe conducted a public dialogue to investigate public opinions on genome editing technology and its implications for biosciences research. The public dialogues took place late 2019 and early 2020 in four European countries: the UK, Czech Republic, Germany and Sweden. These dialogues have served as an instrument to support and encourage ORION overarching goal: embedding Open Science and Responsible Research and Innovation (RRI) principles in research funding and performing organisations (RFPOs).

Ipsos MORI, a global market research organisation was commissioned to implement the full dialogue project, which consisted of a series of open dialogues in four European countries, corresponding to ORION project task 3.3.2. ORION partners at the Babraham Institute (BI) in the UK managed the project with support from participating ORION partners at the Central European Institute for Technology (CEITEC) in the Czech Republic, the Max Delbrück Centre for Molecular Medicine (MDC) in Germany and Vetenskap & Allmänhet (VA) in Sweden. An international Advisory Board and four Institutional Review Groups provided further oversight and governance.

The project was originally designed by the ORION coalition (ORION Task 3.3.1, D3.2) in 2018 and the specifics refined by Ipsos MORI in collaboration with BI, in consultation with the Advisory Board and Review Groups, during 2019. Materials shared with the public during the events were co-designed with internal and external stakeholders from each participating organisation. The public dialogue events lasted 1.5 days in each country, counted with over 30 members of the public and took place between October 2019 and February 2020. Ipsos MORI produced four reports gathering all the findings of each country and one 'synthesis' report highlighting similarities and differences.

The key aims for this project were:

- 1. To understand the public's hopes and fears with regards to genome editing
- 2. To understand when and how to engage audiences with disruptive technologies
- 3. To understand how public engagement strategies might differ between countries
- 4. To contribute towards increasing knowledge and embedding Open Science and RRI in RFPOs
- 5. To contribute towards enriching and improving the quality of existing training on RRI and Open Science

Main conclusions:





Aim 1. This project has given an insight into the public's hopes and fears regarding genome editing, as illustrated in sections 3 & 4 in the dialogues' reports (Annexes 1 - 5). Participants were most accepting of somatic genome editing for medical purposes while germline genome editing of human traits was deemed unacceptable. Public acceptability of the use of genome editing technology was underpinned by avoiding harm and suffering, and protecting social justice, human rights, fairness and equity.

The synthesis report provides a comparison across countries on the findings of this dialogue. This comparison showed differences with regard to participants' concerns about genome editing, with safety being the main one in the UK, its impact on nature and equality of access to the applications in Germany, ethics and social justice in Czech Republic while the Swedes concerned about prioritising research funding and issues around data protection. In all four countries, basic research was positively received and viewed as necessary for scientific developments in tackling disease and improving health.

Aim 2. Section 5 in the reports outlines the findings regarding when and how to communicate and engage audiences with the topic of genome editing. Despite the public valued the public dialogues events as a method for engagement, they acknowledged it had a limited reach. Accordingly, one of the main conclusions was for selecting engagement methods that reach the largest proportions of the public and put scientists who use the technology at the forefront. To be able to make a broader generalisation about communications and engagement with emerging technologies, a more detailed study is required comparing this project with previous related ones about other technologies (Artificial Intelligence, Synthetic Biology, Mitochondrial Donation, Genetically Modified Organisms).

Aim 3. Discrepancies on engagement methods appeared across countries when using an art piece, commissioned for this project, as a method for engagement. Participants deemed the method niche and thereby unappealing for some sectors of society. Importantly, reactions on the art piece differed considerably given the presence or absence of the artist.

Aim 4. These public dialogues have contributed towards increasing general knowledge and practice of Open Science by involving multiple stakeholders from the public to scientists, policy-making, to engagement and communication professionals. This public dialogue project has also been presented in seminars and conferences by ORION staff, to share a practical example of implementing Open Science. Two scholarly articles are in preparation to share ORION learnings on conducting public deliberation activities and public attitudes with genome editing. All of these activities seek to contribute raising awareness about Open Science and Responsible Research and Innovation. Finally, the findings of this dialogue will be used to inform the next round of public engagement strategy at participating organisations, which feeds into the overall governance of the organisation, supporting this way to embed Open Science.





Aim 5. ORION's public dialogue project helped to realise that there is an information void in some participating organisations with regard to genome editing uses, potential risks and benefits, and guiding regulations, for both internal and external audiences. Participating organisations are discussing internally how to address this gap. As an outcome of the dialogue project to address this, we will produce resources that could serve as supporting information for science education and engagement. These resources could be used as well for training purposes for research staff and scientists at different career stages in all participating organisations. This way, public dialogues would be contributing to implementing RRI principles and raising further awareness about Open Science.





1. Introduction

As part of the Horizon 2020 funded ORION (Open Responsible research and Innovation to further Outstanding kNowledge) project, four life science and biomedical research organisations in Europe conducted a public dialogue to investigate public opinions on genome editing technology and its implications for biosciences research. The public dialogues took place late 2019 and early 2020 in four European countries: the UK, Czech Republic, Germany and Sweden. These dialogues have served as an instrument to support and encourage ORION overarching goal: embedding Open Science and Responsible Research and Innovation (RRI) principles in research funding and performing organisations (RFPOs).

The expected benefits of this dialogue project linked back to the overarching aims of the ORION project, which are:

- 1. Increasing the general knowledge of RRI and Open Science practices
- 2. Contributing to changes in RFPOs governance settings that are consistent with Open Science and RRI
- 3. Enriching and improving the quality of existing training on RRI and Open Science

The public dialogues have contributed towards aim (1) by involving multiple stakeholders from the public to scientists, policy-making and engagement professionals. The public dialogue project has also been presented in seminars and conferences by ORION staff, showcasing a practical example of implementing Open Science and helping to raise awareness.

CEITEC and BI will update in 2022 their public engagement strategies, which will feedback into the overall governance and strategy of these organisations and will contribute this way towards ORION aim (2). MDC is currently developing a new strategy for the institute, which will be implemented from 2021. Lessons learned from ORION's public dialogues will inform the public engagement part of MDC's new strategy. VA will use the dialogue's findings to inform policy makers and other stakeholders interested in methods on how to involve and engage the public in discussions on emerging technologies. Furthermore the knowledge VA gained will help them to further develop their public dialogue method and to use it in other projects.

The public dialogues lessons that will inform next round of public engagement strategies at participating organisations will be shared in a scholarly article and a policy paper open to the whole scientific community and which will constitute one of the basis of the communications campaign for this public dialogue (section 3.2).

ORION's public dialogues helped to realise that there is an information void in some participating organisations with regard to genome editing uses and guiding regulations, both





for internal as for external audiences. Participating organisations are discussing internally how to address this gap in the medium term future. The current proposal is to produce resources that could serve as supporting information for science education and engagement by in house scientists and higher management. Furthermore, these resources could be used in training programmes for research staff and scientists at different career stages in all participating organisations, contributing thereby to ORION aim (3).

2. Dialogue Design and Delivery Method

2.1. Overview and Timings

The table below outlines the key stages in this public dialogue project and the deviations to the estimated timeline (reported in D3.2) where they existed.

	Public Dialogue Stages	Estimated Timeline	Actual Timeline
1	Recruit Advisory Board members	May 2019	May-June 2019
2	Commission public dialogue to delivery contractors	May 2019	July 2019
3	First consultation with Advisory Board to discuss public dialogue strategy, specification and stimulus material options	June 2019	June-July 2019
4	First consultation with Review Group from participating organisations	July 2019	June-July 2019
5	Development of public dialogue stimulus material and other required resources	July, August 2019	September- October 2019
6	Stakeholder workshops	September 2019	September – October 2019
7	Second consultation with Advisory Board to feedback on developed stimulus material	September- October 2019	October 2019
8	Second consultation with Review Groups to feedback on developed stimulus material	September- October 2019	October 2019
9	Amend stimulus materials if necessary	October 2019	October- November 2019
10	Public dialogue planning and delivery	May – October 2019	October 2019 – February 2020
11	Reporting	February – March 2020	February – August 2020
12	Preparation of a public engagement framework on disruptive technologies	April – June 2020	September – December 2020



2.2. Governance

An interdisciplinary international Advisory Group was assembled to provide oversight and guidance of the public dialogues project specification. The Advisory Group membership consisted of stakeholders with knowledge and expertise in diverse areas of genome editing.

The following areas of expertise/influence were represented in the Advisory Board:

- Public participation. Simon Burall, Senior Associate, Involve Foundation (UK).
 Involve is the UK's leading public participation charity and Mr Burall has extensive experience in the fields of democratic reform, open government, public participation, stakeholder engagement, accountability and transparency, scientific and technology innovation and organisational change.
- **Scientific Community**: Marta Agostinho, Coordinator, EU-LIFE. EU-Life is an alliance of 14 research centres across Europe. All ORION organisations participating in this dialogue are members of EU-Life.
- Patient involvement: Luca Franchini, psychologist, MSc. Social, Work and Communication Psychology, Fondazione ANT Italia Onlus (IT). ANT is a support network for cancer patients and relatives and a member of ORION consortium.
- **Science communication**: Prof. Annette Leßmöllman, Vice-Dean, Faculty of Humanities and Social Science, Karlsruhe Institute of Technology, (Germany).
- **Public Sector/Government**: Teresa Giménez Barbat, former Member of European Parliament, founder of Euromind, a platform to foster dialogue between the political and scientific spheres.
- **Scientific Community**: The late Professor Michael Wakelam, Director, Babraham Institute, Cambridge (UK).


In addition, ORION staff leading this project at participating organisations also joined the Advisory Board:

- Dr. Nikola Kostlánová, Scientific Secretary, Central European Institute for Technology, CEITEC (Czech Republic).
- Dr. Luiza Bengtsson, Wissenstransfer and Outreach, Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, MDC (Germany).
- Maria Hagardt, International Relations & Communications Manager, VA (Sweden).
- Dr. Stepahnie Norwoods, Public Engagement Officer, Babraham Institute, BI (UK).

These ORION staff served as a link between the Advisory Board and Review groups (nee Internal Management Groups as refered to in D3.2) set up in each participating organisation. The composition of the Review Groups in the different organisations is sumamrised in the table below:








Legend: Higher Management: Professors, Sr Group Leaders; Scientists: Group Leaders, postdocs, PhD students; Public Engagement/Science Communications/Admin; Research Strategy: Postdoc office, R&D Managers, Grants; Funders; Policy-makers; ORION Staff.

BI, in collaboration with MDC, CEITEC and VA, led the design, coordination and development of this project. Staff within the Public Engagement team at BI worked directly with subcontracted Service Provider Ipsos MORI to coordinate and manage the project on a day-to-day basis, sending supporting project materials to the Advisory Group and Review Groups for comments and approval (more on this below).


The diagram below depicts the governance structure of this project.







The diagram below depicts each stage of the process of this project in the UK; other countries had the same workflow.



This whole process described above was first conducted in the UK, a country with a long history of public engagement in science and where ORION task leader is based. The process followed suit in Germany, Czech Republic and finally Sweden.

2.3. Planning and Design

Project materials and responsible organisation:

- Project specification: Initial document produced by the ORION consortium (D3.2), led
 by BI. It was further refined during 2019 between commissioned organisation Ipsos
 Mori and the ORION consortium. It outlined the background, context and rationale
 behind the project, the aims, objectives and proposed methods, the expected outputs
 and outcomes, anticipated risks, and proposed method of disseminating findings. It
 also outlined the purpose and proposed method for evaluating the dialogues.
- Method notes: Document produced by Ipsos MORI in response to the project specification and discussions held between Ipsos MORI and BI. The method notes outlined a detailed plan for the approach taken to the public dialogue project, including the planned recruitment process, event design and content, analysis and reporting of the data and staffing and management of the project.
- Research materials: These were the materials used during the public dialogue events.
 This included the discussion guides used by moderators in the events, the plenary
 presentation slide deck shown to the public, the science art piece used as engagement
 tool (section 3.2) and case study handouts for participants providing examples of how
 genome-editing techniques are currently used by researchers at participating





organisations. The case studies were provided and designed by scientists leading those research projects (section 3.2).

In Sweden, VA led the development of the public dialogue following the method notes and research materials developed by Ipsos Mori. In the otehr three countries, Ipsos MORI managed the project an facilitated the public dialogue events.

2.4. Recruitment of public participants

Recruitment of participants to the public dialogue events was undertaken by the qualitative research recruitment specialists Criteria, a sub-contractor of Ipsos MORI. In order to recruit participants, Ipsos MORI developed recruitment materials which Criteria's recruiters used to recruit participants to the events. These recruitment materials consisted of a set of documents which provided information about the research to potential participants, incorporated a screening questionnaire, which collected information about participant characteristics, and had space to record contact details if participants confirmed they were available and interested in participating.

Recruitment was conducted face-to-face in and around the cities where ORION participating organisations are located (Cambridge, Berlin, Stockholm and Prague).

3. Outputs

3.1 Case studies

Scientists from participating organisations prepared examples of genome editing uses in research projects that were provided during the events with the public. Below is a list of these case studies of each organisation with a brief description about them.

Babraham Institute (BI):

- Case study 1: Editing model organisms. Researchers use genome editing to edit the DNA of model organisms, such as mice, to try and better understand the role proteins play.
- Case study 2: Epigenetic markers. Researchers use genome editing in this project to study how chemical flags attached to the DNA of female reproductive cells can affect how the DNA is read and used in her children's cells.
- Case study 3: How the immune system works. It outlined how scientists use genome
 editing techniques to try to better understand what causes our immune system to
 decline with age.





Max Delbrück Center for Molecular Medicine (MDC):

- Case study 1: Converting skin cells into egg cells. Example of how scientists are
 exploring whether they can convert skin cells to egg cells in rhinos, a process that
 could help to address the near extinction of the northern white rhino.
- Case study 2: How does titin affect heart growth? Editing the titin gene in mice could help understand why changes in this gene lead to mice having different sized hearts, which might lead to insights into how to correct this change in the future.
- Case study 3: Understanding gene expression. Scientists' use of CRISPR/Cas9 to find out in rats and zebrafish which proteins are responsible for causing albuminuria, a sign of kidney disease where the protein albumin leaks out of kidneys and into urine.
- Case study 4: Editing model organisms Scientists' use of CRISPR/Cas9 to re-create human cancers in mice to study tumour growth and resistance to therapies. They hope this will help them understand how patients can respond to chemotherapy differently.

The Central European Institute of Technology (CEITEC):

- Case study 1: Re-programming immune system cells. Use of CRISPR/Cas to try to develop a new treatment for cancers such as leukaemias and lymphomas, called CAR-T therapy.
- Case study 2: Understanding how plant molecules work. Research project to study how CRISPR and molecules similar to Cas9 are involved in plant's immune systems.
- Case study 3: Understanding how viruses work. Use of genome editing to study how bacteria-infecting viruses work, and how they invade bacteria cells.

Vetenskap & Allmänhet (VA):

- Case study 1: Genetically modified potatoes. Case study about how genome editing
 provides a faster way to edit crops, to study them or improve them by making them
 more nutritious or resistant to pests and extreme weather.
- Case study 2: Genome editing bacteria to produce biofuels. Example of how scientists are working on genetically modifying bacteria to directly produce biofuels from only light and carbon dioxide.
- Case study 3: Understanding how cells function. Example of how genome editing can be used to speed up complex screening processes in research. Scientists are developing a CRISPR/Cas9 screening platform that they can use to study diseases, such as cancer and arthritis, to develop better drugs and treatments.
- Case study 4: Editing embryonic stem cells. This example discussed how scientists
 are using the CRISPR/Cas9 genome editing technique to produce stem cells that will
 not cause an immune reaction, which could be used to treat macular degeneration,
 a leading cause of permanent vision loss in people over age 60.





3.2 'AEON Trajectories of Longevity' Science Art piece

At the beginning of this task, the ORION consortium decided to incorporate a piece of art to this public dialogue as an engagement tool. The aim of this art piece was to encourage participants to discuss the issues arising from a potential future use of genome editing technology.

MDC, on behalf of the ORION project, launched a competition for commissioning this art piece in May 2018. The winning bid was submitted by Emilia Tikka, an artist, designer and PhD candidate at Aalto University, The School of Arts, Design and Architecture in Helsinki. The work 'AEON Trajectories of longevity and CRISPR' depicts a speculative scenario of a genome editing rejuvenation technology embodied as a device for daily use and narrated as a fictional photographic story.





¹ ÆON - trajectories of longevity and crispr: https://www.emiliatikka.com/new-page-1 (accessed on 28th July 2020)



ORION has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 741527.





The photographic exhibition and the fictional representation of the rejuvenation technology were displayed during the second event of the public dialogue in each location.

The conclusion on including art in the dialogues was that such art pieces are effective in engaging people to a certain extent and getting them to think about issues and form their own opinions. However, two limitations were identified. Firstly, the audience should be able to understand the issues the art is depicting. Having written information alongside the art itself is useful. In Sweden, where the artist was able to present her work at the public dialogue event, public views and discourse were more focused to the research topics and questions of the public dialogue. Secondly, some participants regarded this medium as not appealing to all parts of society.

3.3 Four stakeholder workshops

A workshop was held in each country, with over 12 internal and external stakeholders to the participating organisation. The objective of this stakeholder engagement was two-fold: to gather diverse insight for the approach and design of the materials to be shown during the public dialogue events; to act as amplifiers of the public dialogue findings.

The workshops took place during September and October 2019. Participants were identified by ORION staff at participating organisations, in collaboration with Ipsos MORI, and included scientists using genome editing techniques and other experts who expressed views from a legal, ethical or policy context. The table below summarises the type of stakeholder who attended the workshops in each country:





	UK	Germany	Czech Republic	Sweden
Funders	1	-	3	1
Industry Food Science, Pharma	3	-	-	3
Science Policy / Policy making	1	-	3	3
Academia / Scientists	2	4	5	6
Other professionals Law, Ethics, Public Engagement, Communications, Journalism, NGO	4	8	1	2
Representative Bodies Food Science, Public Association	1	1	-	-
Total number of Stakeholders	12	13	12	15

A report outlining the findings of the workshop was produced by Ipsos MORI.

3.4 Four reconvened events with the public

A 1,5 days reconvened event was held in each country with over 30 members of the public to discuss genome editing technology. The event was split in one Friday evening session and a full-day Saturday session the following week, which took place in all countries in the following dates and locations:

- **UK**: 24th October & 2nd November 2019; Michaelhouse Centre, Trinity St, Cambridge
- **Germany**: 6th & 16th November 2019; MDC's offices, Hannoversche Str. 28, Berlin





- Czech Republic: 21st & 30th November 2019; Ipsos Offices, Slovansky dum, Na Prikope 22, Prague
- **Sweden**: 23rd of January & 8th February 2020; National Museum of Science and Technology, Museivägen 7, Stockholm

The goal of the first event on a Friday evening (3h) was to give participants sufficient information to engage in discussions about the use of genome editing techniques and the issues arising from it. Participants were informed about key biological concepts including DNA, genes, the genome, and proteins, thus enabling them to discuss different research uses of genome editing technology. Once participants had learnt about these biological concepts, they were shown and discussed case studies outlining examples of the research using genome editing at the corresponding participating organisation.

During the second event on a Saturday (6h), the case studies were re-introduced to remind participants about the type of research conducted by those organisations. This was followed by a discussion of possible future uses of the technology. The afternoon involved a discussion of how best to communicate and engage the public around genome editing technology, part of which involved capturing participants' views on the commissioned artwork (more on Section 3.2).

With participants' consent, discussions at the events were recorded and notes were taken by the Ipsos MORI team. This information was used to produce the reports containing the dialogue's findings (section 3.5).

Three to four experts attended each of the events and were involved in the table discussions. Their role was to answer questions that the participants had about genome editing technology and associated ethical and societal issues, to talk about their own work around genome editing technology, and to comment where appropriate during the conversations. Experts were either stakeholders who had attended the stakeholder workshop, or were scientists from participating organisation. Ipsos MORI produced guidelines for the participating

	# public participants at events	# experts at events (D1 / D2)
UK	31	3 / 4
DE	29	3/3
CR	32	3/2
SE	31	3/3

experts to introduce the ORION project, rationale and aim of the public dialogue and to outline the eperts' role during the events with the public.

3.5 Four findings' reports and one synthesis report





The findings of ORION's public dialogues in each country have been included in four reports (UK, CR, SE, GE) produced by Ipsos MORI together with an additional synthesis report highlighting similarities and differences across countries. With a delay due to the COVID-19 global pandemic, the reports were finalised in August 2020.

Main key findings from the public dialogues:

- 1. The majority of participants were unaware of genome editing technology. However, those who were familiar with the term had a personal interest in contemporary developments in science and were fairly informed about genome editing.
- Participants understood that genome-editing technology could lead to scientific and clinical developments. However, they only could grasp the benefits of using genomeediting technique in a fundamental research setting when contextualised in the real world. This led to an acknowledgement of the value of fundamental research.
- 3. Participants were more interested in understanding the reasons for using the technology and the expected benefits than the technical information.
- The use of non-heritable (somatic) genome editing for medical purposes was the most accepted while heritable (germline) genome editing of human traits was unacceptable for participants.
- 5. The public acceptability of the use of genome editing technology was underpinned by avoiding harm and suffering, and protecting social justice, human rights, fairness and equity. Despite being positive about the possible benefits of the technology, participants were not willing to let it infringe on these principles.
- 6. Participants really valued having experts at the events to be able to discuss the issues surrounding the technology, they felt it fostered trust, and liked the idea of being able to engage with scientists.
- 7. Given the potentially large impact the technology could have for society, participants favour using engagement methods that reach the largest proportions of the public. Yet, they also acknowledged the need for a two-way engagement.
- 8. Art can be an effective way of sparking debate, with the caveats of this engagement method being perceived as "niche" and requiring relevant supporting explanation when the artist is not present.

4. Next steps

The ORION consortia has designed an outreach campaign to disseminate the public dialogue findings and work towards achieving impact with this project. The dissemination campaign consist on:

4.1. Two scholarly articles

BI will lead a publication for Public Engagement Professionals. In this article, we will aim to contextualise the dialogues' findings in light of past examples of engagement with other disruptive technologies (genetic modification, mitochondrial donation, artificial intelligence





and synthetic biology) to propose a framework for engagement with these technologies for Research Funding and Performing Organisations.

CRECIM will lead another publication for Social Scientists. This article will aim at contributing to the current knowledge on public attitudes with regards to genome editing. We will discuss the findings of ORION public dialogues in light of other relevant studies such as the ORION survey on public attitudes to life sciences research and genome editing²; the UK's Royal Society public dialogue on Genetic Technologies (2017)³, the German barometer on human germline genome editing⁴ and Genomics England public dialogue on Genomic Medicine (2019)⁵.

4.2 Dissemination article at a scientific magazine/journal

VA and BI will lead the publication of a dissemination article targeted at biomedical life sciences originations and researchers. Being eLife an Associated Partner of the ORION project, we hope to be able to publish in eLife magazine a Feature Article. The objective of this article will be to spark the curiosity of scientists at research performing organisations about the findings of this public dialogue to encourage further togetherness and engagement with the public.

4.3 Training materials

We will add to the syllabus of ORION Open Science training resources, information and resources regarding:

- The use of genome editing in fundamental research
- The regulatory standards that guides such research
- The dialogues' findings about the ethical considerations of genome editing
- Recommended strategies for public and stakeholder engagement with disruptive technologies

This will add to the evidence-base to enable fully informed research decisions to help align scientific research with the values, needs and expectations of society.

Furthermore, we will produce a 'how-to' guide on public dialogues and their relevance for open science.

4.4 Event to launch findings

Public dialogue outputs will be combined in a targeted manner to communicate the findings to the dialogue's participating stakeholders and the wider research community. The event will take place after publication of the scholarly articles (either in the academic journals or as pre-prints).

⁵ https://www.genomicsengland.co.uk/public-dialogue-report-published/ (last accessed 24 November 2021)



ORION has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 741527.

² https://www.orion-openscience.eu/node/221 (last accessed 24 November 2021)

³ https://royalsociety.org/topics-policy/publications/2018/genetic-technologies-public-dialogue/ (last accessed 24 November 2021)

⁴ Karlsruher Institut für Technologie, 6th November 2018: http://www.explorat.de/wp-content/uploads/2018/buedeka.pdf (accessed 16tth December 2020)



Target audiences that will be invited include:

- Advisory Board members of this public dialogue
- Review Group members of this public dialogue
- Participants to stakeholders workshops of this public dialogue
- Scientific community (ORION / EU-LIFE, other interested researchers)
- Coordinators from other H2020 Swafs and Horizon Europe 'Enhancement of the ERA' projects
- European Funders practicing RRI

The event will take place online, due to current social distancing and reduced traveling conditions, on 21st January 2021.

All these dissemination activities will contribute towards achieving ORION overarching goal of embedding Open Science and RRI in RFPOs.

5. Evaluation

Due to the high cost both in terms of funding and personnel involvement, two evaluations have been performed with different methodologies and focus.

An internal evaluation on this public dialogue is being carried out by ORION partner CRECIM. CRECIM's evaluation of this task is aligned with the overall evaluation strategy for the ORION project, which aims to provide evidence about its expected impact in terms of facilitating the behavioural, cultural and institutional changes required to embed Open Science and providing insight for improving ORION actions for promoting these changes. This evaluation is part of the deliverables of the ORION project (D5.2, Interim Evaluation on Co-Experiences & D5.4, Final evaluation report on co-experiences), which will be submitted separately.

A second evaluation is being undertaken by Gene Rowe Evaluations⁶, an external consultant with broad experience in evaluating public deliberation projects. This evaluation was commissioned via an Invitation to Tender with sponsoring UK Research and Innovation funds secured by BI. This evaluation focusses on solely the implementation of the public dialogue in the UK and seeks to determine the robustness of the methodology used in the UK. The methodology used in the UK had been reproduced in the other three countries where this public dialogue took place. Accordingly, any strengths and limitations identified in this external evaluation could potentially be extrapolated to ORION organisations in Germany, Czech Republic and Sweden.







Following disruptions by the COVID-19 pandemic, the current timeline to finish this evaluation is scheduled for Q2 2021, after the public launch of the dialogues' findings on 21st January 2021 and subsequent final round of data collection.

6. Conclusions

Part I: Reflection on the findings of ORION public dialogue on genome editing

With these public dialogues on genome editing the ORION consortium sought to gather evidence to help translate the stakeholder engagement dimension of Open Science into organisational practices in four life sciences fundamental research organisations in Europe.

Throughout the process of this public dialogue project, the four participating organisations, in collaboration with the ORION consortium, have looked for approaches to incorporate public deliberation with science in research governance, processes and practices. The dialogues' findings highlighted the importance of sustained public communications and engagement to ensure providing enough opportunities for the public to be informed so that their views could help inform decisions around the deployment of genome editing. Due to the disruptive nature of genome editing technology, early engagement and education were seen as necessary. Inclusion of this topic in the school curricula was suggested.

Participants' struggled to understand the exploratory role of fundamental research and made judgements about the technology based on what impact it could have when applied in the real world. The main concerns identified around genome editing - social justice, equity and fairness - were derived from its potential clinical deployment and not limited to life sciences fundamental research settings. These findings suggests the need for blue skies research organisations to continue bridging the understanding gap between fundamental research and translational research.

Another insightful finding of these dialogues was the appetite of the public for some sort of public-facing documentation about the current state and possible future applications arising from the use of genome editing techniques. Despite the existence of statements on the scientific, ethical, and governance issues associated with human genome editing, such as the ones resulting from the two International Summits on Human Genome Editing (2015; 2018) or the one from the European Ethics in Science and New Technologies Group (2016), such information is not readily obvious or available to non-specialist public.





Part II: Why public dialogue and public engagement are part of open science

Given that genome editing technology has an enormous potential to improve human and animal health and preserve the environment, both International Summits on Human Genome Editing called for a global dialogue to engage a wide range of perspectives and expertise, including patients and the general public.

Since early on its design phase (T.3.3.1, D3.2), this ORION dialogue project has been contributing to the ongoing global dialogue. We participated in the Online International Symposium⁷ of the UK National Coordinating Centre for Public Engagement (NCCPE) Genome Editing Public Engagement Synergy (GEPES) to share the ORION approach to this dialogue.

This project sought to help translating the stakeholder dimension of Open Science to specific practices. By linking public and stakeholder engagement into the research and impacts of participating organisations, public deliberation contributes to the democratisation of science, one of the objectives of Open Science. Furthermore, these ORION dialogues increased the public understanding of and participation in science, as acknowledged by the public participants to the public dialogue events.

Stakeholders' engagement is directly related to engagement of participating organisations. The variety of stakeholders' categories or the number of stakeholders external to the participating organisation who attended the stakeholder workshop (section 2.4) can be an indicative measure of the degree to which participating organisations have engaged with stakeholders.

In order for participating organisations to fully benefit from this public and stakeholder engagement project, two elements would be key to the success of this and other attempts of public deliberation:

1. Build and nurture an engaged audience (public and stakeholders).

The feature that sets public engagement apart from other science outreach approaches is its ability to interact with the audience and support exchange of views and opinions. Building, retaining and nurturing audiences will allow for conversations to be sustained and for participants to become engaged in the long term. A sustained conversation will create bubbles of science ambassadors and allow for diverse opinions to permeate the scientific machinery - furthering this way the trust between scientists and other sectors of society.

⁷ Genome Editing Public Engagement Synergy (GEPES), <u>International Symposium</u>, 21stNovember 2018 (Accessed on 27th July 2020)



_



Public participants for this public dialogue were recruited by Criteria, a sub-contractor of Ipsos MORI – subcontracted Service Providers themselves. This level of outsourcing, together with complexities around General Data Protection Regulations, translated in impossibility of maintaining contact with once engaged public audience participating in this dialogue.

A recommendation for research performing organisations resulting from this project would be to create a multidisciplinary working group that could participate in ongoing discussions on the proceedings of science to help aligning scientific research with the values, needs and expectations of society. The existence of this group will also contribute towards increasing public and stakeholder engagement success rate in a timely manner. As communicated in the European Commission 'Special Eurobarometer 401: Responsible Research and Innovation (RRI), Science and Technology' (2013)⁸, the creation of such a working group will address the opinions of over 48% of citizens in ORION-collaborating countries, bar the Czech Republic, who thought citizens should be consulted and their opinions considered regarding decisions about science and technology. Such a group would support the institutionalisation of open science in RFPOs (more on this below, part III).

2. Customised translation of dialogue's findings for the different internal audiences at participating research organisations.

The dialogues' reports convey a lot of information that is differently relevant to professionals at research performing organisations. A deep knowledge of the proceedings and governance of the organisation is hence required to be able to efficiently excerpt and deliver those messages in an audience specific manner.

ORION organisations participating in this dialogue are currently identifying those internal audiences-specific messages, which will be assembled into appropriate formats to share with each audience. This will support the dialogue's core aim of translating its findings to participating organisations' research, governance and public engagement strategies.

A recommendation for future attempts of a public deliberation would be not only to identify internal target audiences of dialogue's messages, as we did in D3.2, but also to narrow down motivations and interests of those audiences. This will support the customised audience-specific translation of dialogues' findings.

Unfortunately, due to unforeseen circumstances caused by COVID-19 global disruption, some of the planned outputs of this ORION project – such as developing mechanisms to



-



link public and stakeholder engagement back into its research and impacts - are still in progress. This drawback resulted in the corresponding delay in the dialogue's desired outcome of influencing policies at participating organisations so that research is organised and conducted in a more inclusive manner and is aligned to society's needs, views, and expectations.

Part III: How does this public dialogue contribute to open science institutionalisation in research performing organisations?

One of the outcomes desired from this project was to gain new perspectives and insights from the public to understand ethical and societal considerations that could be included in research proposals. As such, BI is collating a list of ethical considerations resulting from the views of public participants. This document will provide evidence for scientists at ORION organisations and associated partners (EU-LIFE and beyond) to align scientific research projects to the public's hopes and fears on genome editing technology. This supporting evidence will be shared with research grant offices to inform grant writing and align research proposals to the needs of society.

Outputs of this dialogue project will serve to expand ORION Open Science training programmes and those already existing in ORION organisations, in particular the findings on the ethical considerations alongside the public engagement with disruptive technologies strategies (section 3).

Briefings containing internal audiences-specific findings of this dialogue will be prepared and shared on due course, with one overarching recommendation: the **creation, maintenance** and nurturing of a dedicated working group on open science. Such group's purpose would be to provide a direct engagement avenue with the wide range of perspectives and expertise with stakes in research and innovation. The group's composition should include as many as possible of following categories: own scientists, social scientists, ethicists, health care providers, patients and their support networks, people with disabilities, policymakers, regulators, research funders, faith leaders, public interest advocates, industry representatives, and members of the general public. The group qualities should be responsiveness and deliberateness.

The findings and processes described above will support interdepartmental collaboration and alignment [of open science aims and practices], supporting this way the progressive institutionalisation of open science at ORION organisations.

Annexes: Ipsos Mori synthesis and country reports

The synthesis report prepared by the company Ipsos Mori is included here. The 4 country reports (UK, Germany, Czech Republic and Sweden) are available on the ORION website on this page.







Public dialogue on genome editing

Country synthesis report

By Ipsos MORI Social Research Institute for the ORION Open Science project

October 2020





Contents

F	oreword	4
Α	cknowledgements	5
E	xecutive Summary	6
1	Background, objectives, and method	8
2	Views on key societal challenges and solutions, and knowledge and awareness of genome editing	14
3	Views of genome editing techniques (current and future)	18
	Communication and engagement	
	Conclusions & Recommendations	
	ppendix A: Case studies shown to participants	
	UK case studies:	47
	Germany case studies:	48
	Czech Republic case studies:	50
	Swedish case studies:	52
A	ppendix B: Future possibilities of genome editing handouts	54
A	ppendix C: Information shown about the art piece	57
A	ppendix D: Glossary of Terms	58
A	ppendix E: Advisory Group members	60
Α	ppendix F: Babraham Institute & Ipsos MORI Project Team	61
Li	ist of tables	
Τá	able 1.1: Table of public dialogue events by country	12
	able 5.1: Table of key differences by country	
la	able 5.2: Table of overall conclusions & recommendations across countries	42
L	ist of figures	
	igure 4.1: Images of AEON Trajectories of longevity and CRISPR	
E;	gure 5.2. Diagram of conclusions & recommendations	16

Foreword

The advent of newer genome editing technologies that can make changes to the DNA sequence of an organism in a faster, more efficient, and more precise fashion has opened up a range of new possibilities, in research areas ranging from agriculture and food science, to basic bioscience and medicine. Ultimately, this technological progress has the potential to significantly improve human and animal health.

Realising this potential can only be achieved when scientific and technological developments evolve hand in hand with society. When one informs the other and *vice versa*. What benefits will the technology bring to citizens and under which circumstances do citizens accept those? As globalisation and digital platforms bring citizens closer together, and science increasingly becomes more open, do public attitudes differ across countries?

This synthesis report summarises the findings of an international dialogue conducted in the United Kingdom, Germany, Sweden and the Czech Republic. These national dialogues explored the views of the public to the use of genome editing in a research context and the potential future applications derived from it, the associated trade-offs and how research organisations should engage in the public discourse. This synthesis report highlights that public attitudes across countries remain fairly similar with regards to acceptability of genome editing uses and applications, with non-heritable genome editing for medical purposes the most acceptable possible future use, provided it was for tackling serious and severe life-threatening conditions and diseases. There were nuance differences in the trade-offs with Sweden, Germany and the Czech Republic valuing equality of access to the benefits of the technology over anything while in the UK the safety of possible applications was the prevailing compromise. Approaches to engaging citizens tended to prioritise wider reach methods over depth of knowledge exchange.

The findings of these dialogues are valuable evidence of the continued relevance of social justice as a prevailing value guiding scientific and technological development. With the forthcoming publication of the World Health Organisation Global Governance Framework, which includes ethical considerations and public engagement as key elements for its development, the findings of this dialogue are reassuring and make a timely contribution to ongoing discussions in this area in participating countries and globally.

Dr. Tacita Croucher, Public Engagement Manager, Babraham Institute, Cambridge (UK)

Dr. Luiza Bengtsson, Knowledge Exchange and Outreach, Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, Berlin (Germany)

Maria Hagardt, International Relations & Communications Manager, VA (Public and Science), Stockholm (Sweden)

Dr. Pavla Foltynová, Head of Strategy and Science Department, Central European Institute of Technology, Brno (Czech Republic)

Acknowledgements

The international public dialogues were funded by the ORION Open Science project¹, with the UK ORION partner, the Babraham Institute, acting as the lead organisation.² The authors of the report would like to thank the staff in the Public Engagement Team at the Babraham Institute for their support, as well as members of the international Advisory Group and Review Groups who reviewed drafts of the materials used in the public dialogue events and the reporting outputs from the public dialogue. We also thank the team members at Ipsos Germany and Ipsos Czech for their role in organising and delivering the events in their countries.

We would also like to thank all the stakeholders who participated in the stakeholder workshops and contributed to the development of the materials used in the public dialogues, as well as the experts who attended the public dialogue events and participated in discussions. The names of the stakeholders and experts who participated in the events in each country can be found in their respective country reports which are published alongside this overarching report.³

Most importantly, we would like to thank all of the members of the public who participated in the public dialogue events.

Members of the Advisory Group who have agreed to be named in this report are listed in Appendix E. The Babraham Institute's Public Engagement Team and the project team at Ipsos MORI who authored this report are listed in Appendix F. Members of the Review Groups and Ipsos teams in each country are listed within the respective country reports.

¹ https://www.orion-openscience.eu/about

² https://www.babraham.ac.uk/

³ These reports can be accessed here: https://www.orion-openscience.eu/publications/report-and-papers

Executive Summary

The ORION consortium⁴ commissioned Ipsos MORI to conduct a series of public dialogues focused on the views and concerns of the public regarding the application and implications of using genome editing⁵ technology in ORION research institutions. Events were held in four countries where ORION partner institutions are located; the UK, Germany, Sweden and the Czech Republic. **This report synthesises findings from across the dialogues held in the four countries.** During the events, members of the public discussed applications of genome editing technology, possible future uses of the technology, and explored the best ways for the ORION partners to engage with the public about genome editing.

Views on key societal challenges and solutions

Societal challenges identified across countries were interlinked, including: economic inequality and poverty, climate change and food production, and physical and mental health including disease. Country specific concerns we also raised, such as access to healthcare in Germany. Participants across countries proposed similar solutions to these challenges. Although genome editing technology was not explicitly mentioned, solutions that genome editing has the potential to help realise were raised, including scientific, technological, innovation and research-based advances.

Knowledge and awareness of genome editing

While participants started the dialogue with a basic understanding of key biological concepts, in all countries, knowledge of genome editing technology was low. Participants found it easier to understand and relate to real world examples of how the technology could be applied. Across all countries some concerns related to the technology were raised at this stage, around ensuring how it will be used in safe, ethical, and fair ways.

Views of current and future uses of genome editing technology

Current basic research being carried out (even if it would not lead to real-world applications) was viewed positively and necessary for scientific developments in tackling disease and improving health. Some specific concerns were raised in each country about how genome editing technology was being used, relating to safety, ethics, equality of access and the impact on nature.

Several projective case studies were used to explore possible applications of the technology. Across all countries acceptability of the potential applications of genome editing technology was linked to the direct benefits to humans and health. For example, 'somatic genome editing' was attractive to participants because of the potential of this application to alleviate serious life-threatening diseases. Conversely, applications that participants cautioned were those deemed risky to humans, such as heritable 'germline genome editing', and

⁴ ORION (Open Responsible research and Innovation to further Outstanding kNowledge) is a four-year (May 2017 - April 2021) project funded by the European Union's Horizon 2020 Research and Innovation Programme (agreement No. 741527) under the Science with and for Society (SWAFS) Work Programme, to build effective cooperation between science and various sectors of society.

⁵ The advent of the CRISPR/Cas9 genome editing technique has made genome editing genome faster, more efficient, and more precise, and has instigated a range of new possibilities of the use of this technology, making public discussions about its use relevant and timely.

⁶ 'Somatic genome editing' refers to edits in cells other than embryos, sperm and eggs, so that changes made to the genome are not heritable.

⁷ 'Germline genome editing' refers to editing the genomes of embryos, sperm and eggs, so that changes made would be inherited by future offspring.

those viewed as being unnecessary, such as editing cosmetic traits in humans. Participants could see some benefit of genome editing crops and animals for food production and environmental purposes, but optimism was tempered by concerns around safety and impact of genome-edited organisms on ecosystems.

Communication and engagement

A discussion took place in each country about what scientific research institutions, like the ORION partners, should be saying to the public about genome editing technology, and what are the best methods of engagement. Participants across all countries felt it was important to be transparent about what can and cannot be achieved using the technology to manage public expectations. It is also important to communicate about safety implications of the technology and how it is regulated, to provide reassurance that it is being used in ethical and fair ways. There is a balance to strike between providing enough information to the public and not overwhelming them with technical detail. In Germany and the UK, participants said they wanted to understand scientists' motives for using the technology.

Across all countries it was felt to be important that ORION partners try to engage as many people as possible about genome editing technology given the potentially wide-reaching ramifications of its use, and participants suggested the best ways to do this would be using online and video-based communication approaches. At the same time, participants valued opportunities for two-way engagement where they could hear from experts.

An art piece was used within the dialogues to encourage participants to discuss a hypothetical scenario arising from genome editing technology and to facilitate discussions around ethical implications. The art successfully provoked discussion around these issues, particularly where additional information was provided about it.

Conclusions & recommendations

There were some specific differences in public opinions between individual countries⁸, which are explored throughout this report, but overall, there were overarching similarities in views across all four countries. These views form the basis of the conclusions and recommendations in this report. Awareness of genome editing is low, so ORION should communicate transparently with the public about this technology including potential benefits and risks. ORION partners should be involved in supporting international regulations of the technology and this involvement should be visible to the public. Participants saw value in basic research, and it may be helpful for ORION partners to frame basic research as being exploratory, to help engage the public. There was fairly unanimous support for using somatic genome editing for medical purposes, so ORION partners could focus their future genome editing-based research on advancing this application area, while showing appreciation of ethical considerations of other applications. Participants thought online and video-based engagement methods would have the widest reach, so ORION partners should try to incorporate these methods into public engagement strategies, while simultaneously encouraging two-way methods of engagement where the public can hear from scientists directly. It may be possible for ORION partners to also incorporate art pieces into these strategies, but art should be shown alongside supplementary information to support people in understanding the artwork.

⁸ These differences are summarised in Table 5.1: Table of key differences by country, in the Conclusions & Recommendations chapter of this report.

1 Background, objectives, and method

Background

1.1.1 About ORION

ORION (Open Responsible research and Innovation to further Outstanding kNowledge)⁹ is a four-year (May 2017 – April 2021) project funded by the European Union's Horizon 2020 Research and Innovation Programme (agreement No. 741527) under the Science with and for Society (SwafS) Programme, to build effective cooperation between science and various sectors of society.

The mission of the ORION project is to explore ways in which Research Funding and Performing Organisations (RFPOs) in life sciences and biomedicine can open-up the way they fund, organise and perform research. The project aims to trigger evidence-based institutional, cultural and behavioural changes in RFPOs, targeting researchers, management staff and high-level leadership.

The vision of the ORION project is to "embed" Open Science and Responsible Research and Innovation (RRI) principles (ethics, gender, governance, open access, public engagement, and science education) in RFPOs, their policies, practices and processes.

The consortium of organisations participating in the ORION project is composed of:

Five Research Performing Organisations:

- The Babraham Institute (Cambridge, UK)
- Fundacio Centre de Regulacio Genomica (Barcelona, Spain)
- The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (Berlin, Germany)
- The Central European Institute of Technology Masaryk University (Brno, Czech Republic)
- The Centre for Research in Science and Mathematics Universidad Autonoma de Barcelona (Barcelona, Spain)

Two research funders:

- Instituto de Salud Carlos III (Madrid, Spain)
- Jihomoravske Centrum pro Mezinarodni Mobilitu (Brno, Czech Republic)

Two research supporting organisations:

- Vetenskap & Allmänhet (Stockholm, Sweden)
- Fondazione ANT Italia onlus (Bologna, Italy)

⁹ https://www.orion-openscience.eu/

1.1.2 About this public dialogue

In July 2019, the ORION consortium commissioned Ipsos MORI to conduct a series of public dialogues about the views and concerns of the public regarding the application and implications of the research performed by ORION institutions using genome editing technology. Four ORION partners participated in the project (throughout this section, the term 'project' is defined as the series of public dialogues in four countries), three of which are organisations performing life sciences research and one of which specialises in public engagement in science:

The Babraham Institute, Cambridge, UK - https://www.babraham.ac.uk/

Publicly-funded, world-class research institution, undertaking innovative biomedical research in over 20 research laboratories that collectively focus on understanding biological mechanisms underpinning health and wellbeing throughout the lifespan.

Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany - https://www.mdc-berlin.de/

One of the world's leading research institutes in life sciences and member of the Helmholtz Association of German Research Centres, Germany's largest scientific organisation. MDC conducts basic biomedical research to understand the causes of diseases at the molecular level with the mission to translate discoveries as quickly as possible into practical applications, aiming to improve disease prevention, diagnosis and therapy.

The Central European Institute of Technology (CEITEC), Brno, Czech Republic - https://www.ceitec.eu/

Established in 2009 as an independent institute focused solely on research, since 2011 it operates as a consortium consisting of four leading Brno universities and two research institutes that joined forces to establish a superregional centre of scientific excellence combining life sciences, advanced materials and nanotechnologies.

Vetenskap & Allmänhet (Public & Science; VA), Stockholm, Sweden - https://v-a.se/english-portal/

Non-profit association established in 2002 with the purpose of promoting dialogue and openness between researchers and the public. VA has around 90 member organisations representing research organisations, public authorities, institutes and universities as well as companies and private associations. VA acts as a knowledge hub for public engagement and science communication in Sweden, disseminating knowledge and experience, gained by itself and others, and developing toolkits and best practice guidelines.

This report synthesises findings from across the dialogues held in the four countries. There are also individual country reports available, these report on findings from each country separately.¹⁰

¹⁰ These reports can be accessed here: https://www.orion-openscience.eu/publications/report-and-papers

Aims and Objectives

Genome editing technology is a broad term describing a collection of methods that enable changes to be made in DNA - the genetic material of all cells. Whilst genome editing techniques have been available for many years, the advent of the CRISPR/Cas9 genome editing technique has made targeted editing of the genome faster, more efficient, and more precise. This has opened up a range of new possibilities, in research areas ranging from agriculture and food science, to basic bioscience and medicine. The genome editing technique CRISPR/Cas9 provides a good model of a recent disruptive biotechnology. Disruptive technologies are those that have the potential to impact society, are able to displace an established technology, shake up an area of research, or create a completely new area of research.

The aim of ORION's public dialogues was to explore public views regarding the research that ORION partners conduct using genome editing technology and possible future potential applications of this technology and to gather evidence on when and how research-performing organisations should engage with society about disruptive technologies.

Specifically, the dialogue sought the following objectives:

- How do the public trade-off the benefits and dis-benefits and potential unintended consequences arising from genome editing?
- Under what conditions are the public willing to make these trade-offs? For example, in what contexts and for what purposes?
- To understand the boundaries of acceptability of the technology, as well as what reassurances the public needs in order to support the use of the technology.
- What are the public's hopes and fears regarding the ORION partner's research using genome editing?
- What mechanisms should ORION partner organisations use to be open about their research and at what stage in the process should the organisations engage with the public?
- To understand how public engagement strategies might differ between countries within the ORION partnership.

Participating ORION organisations sought to increase two-way engagement with the public in order to make better decisions informed by a wide range of views and values, about how and when to engage with the public on disruptive technologies; and to develop mechanisms that provide links for public and stakeholder engagement back into its research and impacts. Findings from this dialogue are also intended to be transferrable to other areas of disruptive science and technology outside of genome editing.

Method

The dialogue within each country had important input from the ORION participating organisations and their national stakeholders. These groups provided input into the materials in order to ensure they reflect the

genome editing research carried out by the participating research organisation and the national context of the use and regulation of genome editing within each country. In addition, scientists and other technical experts from participating organisations and their networks joined in the dialogue events to provide specific knowledge and expertise.

The dialogue method used in each country is outlined in each of the individual country reports. A consistent approach was followed across the four countries to support analysis of the entire dataset, leading to the production of this final synthesis report that summarises the main conclusions and similarities and differences across countries.

1.1.3 Public Dialogue workflow

All stages of the public dialogues were carried out in the UK initially, followed by the other three countries, which replicated the approach taken in the UK. The events took place in the UK first because the UK ORION partner, the Babraham Institute, led the project. The decision to run the events firstly in the UK was made in the context of the UK having a long-standing tradition of public engagement in science.

Overall, the project proceeded in the following stages:

- **1.** The ORION consortium commissioned Ipsos MORI to run a project consisting on a series of public dialogues in four European countries and developed the project specification.
- **2.** Ipsos MORI worked with the Babraham Institute, the ORION partner leading the project, to develop the materials to use at a stakeholder workshop.
- **3.** A workshop was held with key stakeholders in each country, with expertise in genome editing, policy, ethics, law, and science communication and engagement. The purpose of this stakeholder workshop was to provide a diversity of insight into the framing and scoping of the materials to be shown during the public dialogue events. The date and location of the stakeholder workshop in each country is outlined in the table below.
- **4.** Findings from the stakeholder workshops were used to help develop materials for the public dialogues. Each institution provided three to four examples of their research using genome editing to present to the public in the form of case studies.
- **5.** The research materials¹¹ used in the public dialogue events were initially reviewed by the Babraham Institute and adaptations were made by Ipsos MORI. The Advisory Group¹² commented on a revised set

¹¹ Research materials – these were the materials used in the public dialogue events. This included the discussion guides used by moderators in the events, the plenary presentation slide deck shown to the public, and case study handouts for participants providing examples of how genome editing techniques are currently used by researchers in each country.

¹² An international Advisory Group was convened to provide oversight and governance of the overall project (the term 'project' is defined as the series of public dialogues in four countries). The Advisory Group membership consisted of international stakeholders with knowledge and expertise in genome editing, the ethical issues associated with the technology, and science communication as well as senior management from each of the four ORION partners involved in the project.

- of materials and further changes were made. A Review Group¹³ within each country then further reviewed the materials before they were finalised. A list of members of these groups can be found in the appendices of the individual country reports.
- **6.** A pair of public dialogue events within each of the four countries were held with roughly 30 members of the public (one on a weekday evening and the other on a Saturday 1-2 weeks later). A staggered approach was taken, with events first being carried out in the UK, followed by Germany, Czech Republic then Sweden. The dates and locations of the events in each country are outlined in the table below. Experts attended each of these events, their role was to ensure that the genome editing technology and related ethical and societal issues were presented in an accurate and balanced way, and to answer questions that the participants had about these issues.
- **7.** Findings from these events were written up into four country-level reports, and this overarching synthesis report pulling together findings from across the countries.

Table 1.1: Table of public dialogue events by country

	Stakeholder workshop	Event 1	Event 2
UK	10th September 2019	24th October 2019	2nd November 2019
Germany	23rd September 2019	6th November 2019	16th November 2019
Czech Republic	18th September 2019	21st November 2019	30th November 2019
Sweden	2nd October 2019	23rd January 2020	8th February 2020

1.1.4 Public dialogue events

In order to recruit participants to the public dialogue events, Ipsos MORI developed recruitment materials to be used by each country's recruiters. These recruitment materials consisted of a set of documents which provided information about the research to potential participants, incorporated a screening questionnaire which collected information about participant characteristics, and had space to record contact details if participants confirmed they were available and interested to participate in the research.

¹³ A Review Group was set up within each country to help framing the public dialogue materials to reflect the national and institutional context.

The screening questionnaire asked about demographic factors including participants' gender, age, ethnicity, parental status, employment status, sociodemographic segment and where participants lived. Quotas were set on these variables to reflect the national population and ensure diversity in the participants attending the events, with recruitment of particular groups of participants stopping once that quota had been achieved. Participants were also asked about their awareness of and attitudes to genome editing technology and quotas were set on this.

The approach taken by the recruiters in each country differs slightly and specific details of each country's recruitment process can be found in the individual country reports, as well as further details about the structure of the public dialogue events.

The two events of the reconvened public dialogue events served different purposes:

Event 1 (3-hour evening workshop): The focus of this event was to give participants the minimum amount of information needed to engage in discussions about the use of genome editing technology and the issues arising from it. Participants were informed about key biological concepts including DNA, gene, genome, and proteins, this enabling them to discuss different research uses of genome editing technology. Once participants had learnt about these biological concepts, they were shown and discussed case studies based on their country institution's research using genome editing.

Event 2 (day long Saturday workshop): During this event, case studies outlining their country institution's research were re-introduced to remind the participants about the type of research currently conducted in their country, and this was followed by a discussion of possible future uses of the technology. The afternoon involved discussion of how best to communicate and engage the public around genome editing technology. Part of this conversation involved capturing participants views on an artwork that was specially commissioned for the dialogue, which depicted a possible far off future where genome editing technology has enabled the slowing down of the ageing process.

2 Views on key societal challenges and solutions, and knowledge and awareness of genome editing

At the start of the first dialogue event in each country, participants were invited to think about key challenges and problems facing society, how they imagine those challenges could be solved, and what role technology could play. This allowed people to feel comfortable talking about issues and also revealed if their stated societal challenges overlapped with the benefits that can potentially be realised by genome editing. Participants' knowledge and awareness of genome editing was also gauged.

Many societal challenges identified across countries were similar and often also interlinked

Similar societal challenges were raised across the four countries. These fell into three main themes:

- 1. economic inequality and poverty;
- 2. overpopulation, climate change and food production; and,
- **3.** challenges related to physical and mental health, including disease.

The challenges raised were often interlinked. For instance, challenges around resource inequality (access to medicines/healthcare and resources such as food not being shared fairly) were discussed in the context of a growing world population. Environmental concerns such as climate change and plastic in our oceans were linked with issues of sustainable food production.

"Climate change we've also got. Famine and lack of water resources. As a way to try and reduce famine, [there needs to be] at least improved food production throughout the world."

Event 1, Cambridge, UK

Some country-specific challenges were also raised. These were:

- Brexit, the rise of populism and identity politics were mentioned as challenges facing society in the UK.
- In Germany, access to healthcare within a system of public/private health insurance was raised as a concern, and related to this, the power of pharmaceutical companies was concerning for participants. The unknown impact of genetically modified crops and perceived lack of regulation of this were also concerns.
- In the Czech Republic, participants mentioned poor quality foods replacing natural ingredients. They also spoke of concerns relating to globalisation in terms of the power of global corporations and non-democratic states.

• In Sweden, participants were concerned about the spread and control of global pandemics. Participants were also concerned about digital security – how secure their personal data was, and who is able to access this.

Participants across countries offered similar solutions to these, including political and economic solutions as well as scientific, technological, innovation and research-related solutions

Solutions offered by participants to these key challenges tended to fall into two categories which were consistent in each of the four countries.

1. Political and economic solutions: in relation to funding resources and research which could address the challenges discussed above and the sharing of resources more equitably to address economic inequality. In Germany, the Czech Republic and Sweden, the importance of improving education was discussed at this stage of the dialogue.

"There needs to be more money. So, resource to tackle disease."

Event 1, Cambridge, UK

2. Scientific, technological, innovation and research-related solutions: in relation to tackling food and health challenges, for instance, developing technologies to make crops more durable, and using science and technology in healthcare to improve diagnoses and prevent diseases. This second category contains solutions that genome editing technology could potentially deliver.

"Global food sufficiency cannot be solved with the use of convention tools. Science must step in."
Event 1, Prague, Czech Republic

The solutions proposed by participants in each of the countries fell into the two broad categories outlined above, but participants in each country considered different specific examples and solutions. These related back to ways to solve the key challenges that they had previously discussed:

- In the UK, participants suggested the use of laboratory grown meat products could help to tackle climate change by reducing the need for farmland and reducing greenhouse gas emissions. They also suggested access to healthcare could be improved using video conferencing technology or other innovative communication methods.
- In Germany, participants thought that technology could be used to optimise treatments or assist in early diagnosis (using technology to speed up diagnosis was also mentioned in the UK).
- In the Czech Republic, participants mentioned global sharing of information and joint scientific practices as potential general solutions to the challenges they raised.
- In Sweden there was an emphasis on the need to fund research to combat all the challenges raised.

While participants started the dialogue with a basic understanding of key biological concepts, in all countries the general knowledge of genome editing technology was low

Across all countries there was a basic understanding of key biological concepts, but participants were mostly unaware of genome editing technology. Only a few participants within each country knew about it from the start.

As soon as they learnt about genome editing technology, participants were looking for what the real-world benefits of the technology could be, such as medical advances. Participants recognised that genome editing had the potential to be a powerful technology and were interested in the opportunities it presented.

"Cool. I am excited that we are so far that we can cut out specific things out of the genes and replace it with something else. These are incredible opportunities."

Event 1, Berlin, Germany

"I see endless opportunities. It is positive for treating diseases, growing resilient plants, not even so much water will be needed."

Event 1, Prague, Czech Republic

Some concerns around safety, ethics and fairness of the technology were also raised at this stage across the countries. Details of the differences by country around this are outlined below:

- When participants in the UK were first introduced to genome editing technology, they expressed concern that not everyone in the scientific community would use genome editing techniques responsibly. Trust in scientists and the need for global regulation of the technology was discussed at this stage.
- Participants in Germany firstly associated genome editing technology with the potential to bring benefits
 in medicine. However, they also had concerns relating to fairness and access to the technology at this
 stage that possibly only the wealthy will be able to use it and related this back to the public/private
 healthcare divide in the country. Ethical concerns were also raised at this point over using the technology
 for non-medicinal purposes.
- When Czech participants learned about genome editing technology, they discussed the potential for it being used in agriculture and the food industry, as well as for medical purposes. Czech participants also raised concerns around fairness and safety; they were concerned about the technology being used by special interest groups to push ideologies such as for religious interest, as well as in the interest of non-democratic countries (relating back to the initial challenges about this that Czech participants had raised as facing society).
- In Sweden specifically, participants discussed a need to improve knowledge among the public, including making it clear to people what the distinction is between genome editing and genetic modification, as there was some initial confusion around this (this confusion also came up in the UK dialogue but was raised further along in the discussions). This discussion was reflective of the broader discussion in Sweden on the important role of education in engaging the wider public with genome editing research.

Limitations of current genome editing techniques were also discussed in Sweden at this stage, with help from the experts present.

3 Views of genome editing techniques (current and future)

Basic research was positively received and viewed as necessary for scientific developments in tackling disease and improving health

Participants within each country were shown three to four different case studies of basic research using genome editing techniques currently carried out by the ORION partnership organisation that operates within their country.¹⁴ It was explained to participants that this work being conducted by the ORION partners was typically fundamental biological research ('basic research') aiming at understanding biological processes underpinning living organisms, which may or may not eventually lead to practical applications. The full case study handouts shown to participants in each country can be found in Appendix A.

Participants across the four countries were not initially aware of what basic research was, but they were positive about this research being carried out even if it would not lead to real-world applications in the end. This is because they saw basic research as necessary for scientific development. When they were discussing genome editing generally, participants tended to look to the potential practical, real-world applications of genome editing and discussed whether these were of value (and hence related more to case studies where they could see these practical applications more easily). For instance, research for medical purposes or that would tackle disease was viewed as most valuable and having the most potential; people were excited by the opportunities in this area.

"People suffer. It is a good idea to cure disease, but who has access to it [this technology]?"

Event 1, Stockholm, Sweden

"It's the first step of a long process. Hopefully at the end, it eradicates diseases whatever it may

Event 1, Cambridge, UK

"There are many things in the world that can be abused. As long as it can save lives, I'd go for it!"

Event 1, Prague, Czech Republic

Across the countries, there was support for clear regulation on the uses of the technology on an international scale, and to avoid the risk that the use of the technology being misused and abused.

"It [genome editing] might be regulated in this country but not in others." Event 1, Cambridge, UK

¹⁴ Each case study was presented as a one-page handout. In Sweden, where the ORION partner organisation does not conduct research using genome editing techniques, participants were shown case study examples based on the work of other Swedish scientists.

There were, however, some concerns relating to safety, ethics, equality of access and the impact on nature

Participants across countries discussed similar benefits that could be achieved from the technology. The differences between countries tended to relate to the concerns raised around the technology at this stage. These fell into overall themes of safety, ethics, equality of access and the impact on nature, as discussed below:

- In the UK, some case studies were presented where the practical applications of the technology were less clear and participants struggled to understand these and had a lot of questions around how these techniques are used and how they work. Participants felt it was important that a lot of in-depth research using genome editing technology was carried out before it is used in an applied way, with safety fears at the heart of this. There was surprise about the progress that had already been made with the technology and participants were encouraged to know it was being used widely in UK laboratories.
- In Germany, there was also surprise about the progress that had already been made. Concerns raised were with the technology leading to interference in natural eco-systems, causing unintended effects. There was also concern around the influence those who fund the research have on the research process (this concern was also raised in the Swedish events), and how can it be ensured that there is access for all to the benefits of the technology, not just a select few.
- In the Czech Republic, support for basic research was strong and trial and error was seen as a part of the research process even if it does not lead to applied outcomes. In contrast to the concerns raised by German and Swedish participants, Czech participants felt comfortable with the technology only initially benefitting a few people in society, as they felt it would become more accessible to others over time. However, there was some worry about misuse of the technology by those that have access to it and worsening existing inequalities in society.
- In Sweden, as in Germany, concerns were around who is funding the research and the impact this has on the research process. Participants also felt it is important to consider whether the expense of research is always worth it and what is the best use of money. They argued that research into diseases is important but there needs to be prioritisation the deadlier a disease, the higher priority it should be. They had specific concerns that only wealthy countries would have access to this technology and about potential issues with ensuring personal data protection.

In the Czech Republic and Sweden, participants were also presented with case study examples of research on crops and plants using genome editing techniques. There was some enthusiasm for this research in the Czech Republic, while in Sweden participants were more neutral towards their case study (using genome editing techniques to produce low glycemic index potatoes) and had concerns about potential knock-on effects in nature.

"What happens to the farmers and what are the consequences in nature?"
Event 1, Stockholm, Sweden

There were some indicative differences in views by demographic groups, typically by age and gender, with younger participants and men finding the technology more appealing

As the dialogue events were carried out with small groups of people in each country, these are only indicative findings of differences between different groups of participants.

• Among UK participants, males under 35 tended to be more positive and accepting of the use of genome editing technology, and women less so. Those who were older (of either gender) tended to have more worries about it.

"The knowledge is already there; the practice is already there. Going back to the ethical question if one feels one can't control it how can it ever stop now it has started? Why weren't these questions asked before they started trying to develop it?"

Event 1, Cambridge, UK

- In Germany, participants with higher levels of educational attainment appeared to have a higher awareness of ethical debate and understanding of genome editing. There were differences by gender as men focussed on genome editing as a technological advancement, while women tended to focus on the potential to improve quality of life through genome editing. Like in the UK, older participants tended to have more concerns about the possible unintended drawbacks of the technology.
- Similarly to Germany, in the Czech Republic those from a higher educational background were better able to understand the risks of using these genome editing technology and women tended to focus on the potential health benefits. At the same time, men found the technology appealing because of its low cost and therefore accessibility.

"It is humane. Children who will never be functional, all around suffer with it...It would be beneficial to mankind."

Event 1, Prague, Czech Republic

• In contrast, in Sweden, there were no notable differences in views by demographic groups. Views stemmed from where the conversation began instead. For example, in a group where economic issues were raised early on within the discussions this became a more prominent theme within this group.

"Most research is funded privately and it's hard to know what their vested interests might be." Event 1, Stockholm, Sweden

Somatic genome editing for medical purposes was the most acceptable possible future use of the technology given the potential of this application for tackling serious and severe life-threatening conditions and diseases

Participants were shown a range of future possible uses of genome editing applications, designed to enable them to reach some conclusions around what constitutes acceptable and less acceptable usage (these can be found in Appendix B).

Non-heritable genome editing for medical purposes ('somatic genome editing')

In all countries, 'somatic genome editing'¹⁵ for medical purposes was attractive to participants because of the potential of this application for tackling serious and severe life-threatening conditions and diseases. However, there were also nuances between countries:

- In the UK and in Sweden, participants discussed the use of the technology for non-life-threatening conditions and diseases (like deafness, blindness, Down's Syndrome and Autism). The use of the technology for these purposes was **less acceptable** given the perceived lesser severity of these conditions and (in some cases) the removal of choice for individuals. In these countries, discussions around the uncertainties in curing the disease, and in Sweden the uncertainties in passing on the edited genes to offspring, limited the acceptability for this application of the technology.
- In Germany, while somatic genome editing was initially viewed less efficient than germline genome editing¹⁶ (where changes can be passed on to offspring), as participants discussed this further, they were comforted that the **results will be confined to those who have chosen to have their genome-edited**, thus any unknown effects will not passed on.
- In the Czech Republic and in the UK, the chance that **there could be inequality in access**, with only the wealthiest being able to afford it, hampered enthusiasm among some.

Genome editing plants and crops

There were varying levels of appeal to the application of genome editing in plants and crops across countries, and participants within each country saw some benefits of this:

- In the UK and in Sweden, participants became drawn to the potential of this application in **tackling food insecurity and shortages and solving hunger and food affordability.** In Sweden, participants were also drawn to the idea of editing crops to make them **more nutritious**.
- In Germany, the potential for this application in the context of **climate change** was the factor that made this application of genome editing more acceptable.
- In the Czech Republic, participants did see some value in using the technology on crops in order to make them more resilient to the environment to survive increasing droughts caused by climate change.

However, concerns were also expressed in each country about this application of genome editing technology:

• In the UK and in Germany, there were questions over the unknown effects on humans of consuming genome-edited plants, and the unknowns surrounding the introduction of edited plants into the natural ecosystem. In the UK, some participants automatically associated genome-edited crops with genetically modified crops, which caused some uncertainty.

^{15 &#}x27;Somatic genome editing' refers to edits in cells other than embryos, sperm and eggs, so that changes made to the genome are not heritable.

^{16 &#}x27;Germline genome editing' refers to editing the genomes of embryos, sperm and eggs, so that changes made would be inherited by future offspring.

- In Germany participants initially struggled to see the use of this application of genome editing technology, as food was already considered accessible and affordable.
- In the Czech Republic, this application of the technology was **not considered to be as important as other uses such as those that would tackle disease** with participants unable to justify the apparent need for the use of this application of the technology and instead offering alternative suggestions (e.g. those allergic to gluten can solve this with their diet, rather than modifying wheat to be gluten-free).
- In Sweden, the focus of concerns was around the safety of the technology and specific concerns were raised about **transparency in research and in food labelling**. In Sweden, participants said that they needed to know more about what happened to their food so that they could judge for themselves whether it was safe to eat.

Genome editing animals and livestock

In all countries except Germany, participants recognised some of the potential advantages of editing the genome of animals and livestock:

- In the UK and in Sweden, participants recognised the potential benefits around using genome editing to treat disease and genetic conditions in animals, which would make them healthier. In the UK, additionally, participants liked the idea of genome editing assisting more environmentally friendly farming.
- In the UK and Czech Republic, participants viewed the transplantation of animal organs to humans (known as xenotransplantation) as acceptable if it was proven to be safe, because of the potential life-saving potential for humans. Participants in Sweden also saw the benefit of this but were concerned that there are still too many unknowns to ensure it was safe. In Germany, participants initially found the idea off-putting but eventually came around to accepting it as it could help to support human life.
- In the UK and Sweden, participants could see possible medical benefits of genome editing insects such as editing the ability of mosquitoes to carry malaria.

For several reasons, the concerns and unknowns around genome editing animals and livestock tended to outweigh any benefits, and this reasoning differed slightly between countries:

- In the UK and Sweden, and in Germany (where the application was highly controversial), there were concerns about the **unknown effects on humans of consuming genome-edited animals**. Participants in the UK and in Germany were also concerned over **animal welfare**, if genome editing animals meant they would be treated poorly.
- In the UK and in the Czech Republic, concerns too were raised around the creation of genome-edited livestock interfering with the natural eco-system.

• In the Czech Republic, participants were concerned about genome editing insects interfering with natural ecosystems and disturbing the food chain. In Sweden, while participants could see potential benefits to genome editing insects, they also felt that there were too many unknowns currently to ensure this would be safe.

Heritable genome editing for medical purposes ('germline genome editing')

Across the four countries, there were a mix of quite negative reactions to 'germline genome editing' for medical purposes, though with some subtle country differences explaining the reasoning for this:

- In Sweden, the UK and in the Czech Republic, the risks associated with the potential unknown repercussions for many generations of people was a concern for many. Because of this, in the UK and in the Czech Republic this was the most controversial potential use of the technology. However, in both countries, participants were more accepting of the (future) potential for this application of the technology to be used to treat serious and devasting diseases, for example Huntingdon's disease.
- In Sweden, the concerns about germline genome editing focused around the **creation of a supposedly** 'superior race' of people with superior genes in comparison to everyone else.
- In Germany, initially the potential to eradicate diseases using genome editing technology was viewed with great optimism and participants preferred the use of germline genome editing for this purpose over using somatic genome editing, because they felt that germline genome editing would be more efficient in achieving changes (as changes would be passed on to offspring). As with the UK and the Czech Republic, by the end of the discussion, and after recognising the drawbacks, it was clear to participants that for now, heritable germline editing should only be used to cure or prevent inheritable illness where this was would result in relieving people from suffering.

Genome editing to change or enhance human traits

Universally, across all countries, the use of genome editing technology to enhance or change traits in humans (such as changing eye or hair colour, or increasing endurance) was viewed **negatively and as unnecessary and unnatural**. Across countries, very few benefits were identified. Participants had various objections:

- In the UK, in Sweden and in Germany, participants were strongly against this application of genome editing technology and cautioned the risk of **exacerbating divisions** in society and **creating inequalities** between those who will be able to afford editing their traits and those who will not.
- Additionally, in Germany, there was caution over a society where everyone will be physically similar, and
 one that strives to create a superior race.
- In the Czech Republic this application reduced participants' initial enthusiasm for fast application of genome editing technology being used in practice.
- In Sweden some discussions went as far as to suggest an outright ban of this application of genome editing technology.

4 Communication and engagement

A key research objective for this project was to better understand how the ORION partners should engage with the public about disruptive technologies like genome editing. In the second public dialogue event within each country, a discussion took place about this – what messages should scientific research institutions be communicating to the public about genome editing technology, and how should they be saying these?

As part of the discussion around how and what is the most effective way to communicate the issues arising from genome editing technology, participants were shown the exhibition 'ÆON - TRAJECTORIES OF LONGEVITY AND CRISPR'¹⁷ created for the purpose of these public dialogues, in collaboration with artist Emilia Tikka and one of the ORION partner organisations (MDC, Germany), and were asked to reflect on it.

ORION partners should be engaging with the public transparently around safety and regulation of the technology, and realistic benefits/risks, to manage public expectations

Across all four countries, participants thought that transparency from scientists about genome editing technology was key. Having learnt about the technology at the events, it was clear to participants how powerful genome editing technology had the potential to be. They viewed it has having major potential benefits but also major potential risks. Therefore, it was viewed as important for scientists to communicate with the public about these risks and benefits, this included levels of safety of the use of the technology in different contexts. Participants welcomed to be regarded as stakeholder and to be included in the discussions by ORION partners, particularly where research could lead to applied uses of genome editing technology that would affect their lives.

"I think it's great that you see us as the stakeholder. We're the end users. I haven't experienced the scientific community thinking that way."

Event 2, Stockholm, Sweden

One way to help to achieve this transparency is for scientists to communicate about both their successes and their failures (or if not 'failures' as such, whether the research has found what they were anticipating and why). Participants thought that by doing this, scientists would be able to manage the expectations of the public in terms of what is realistically achievable using genome editing technology, or if that is unknown, what is likely or unlikely to be achievable.

- In the UK participants thought there would be value in scientists communicating where they had not succeeded or where there were difficulties in using the technology.
- In Germany participants suggested scientists should communicate about both the potential positive and negative implications from using the technology.

¹⁷ https://www.emiliatikka.com/new-page-1

- In the Czech dialogue workshops, participants were particularly keen for scientists to communicate about their successes using the technology and the potential benefits of it, using applied examples where possible. In this country discussions focused more on potential benefits than risks.
- In Sweden on the other hand, much of the discussion focused around potential risks of using genome editing technology. To this end, ORION partners should try and communicate risk to the general public, including how new research findings affect how risky or safe a procedure is.

"[Scientists need] To show what benefit it brings in the countries where it is permitted." Event 2, Prague, Czech Republic

"It is important to show up and down sides. Do not sugar-coat it. People should be able to form their own opinion."

Event 2, Berlin, Germany

There was recognition across the countries that the impacts of genome editing technology would not be geographically limited to one nation or continent and that European science organisations like the partners in ORION should collaborate in the development of regulation on the use of the technology and in how it is communicated to the public. The example discussed of the Chinese scientist He Jiankui illegally genetically engineering human twins emphasised this need for international agreement on how the technology will be used ¹⁸

"It [genome editing] might be regulated in this country but not in others." Event 1, Cambridge, UK

- A key finding from the UK public dialogue was the need for there to be some form of internationally agreed and respected public-facing documentation which outlines the current state and possible future applications arising from the use of genome editing technology. This should inform the reader that genome editing techniques, despite being in their infancy regarding their use in applied clinical settings, could bring wide-ranging benefits which cannot yet be predicted with certainty. The public should also be informed about what the current regulations are around genome editing technology what is and is not currently accepted / legal? This documentation would help to answer some of the questions and issues raised through this dialogue around whether the technology is being used in safe, ethical, and fair ways. Participants felt that as scientists working for ORION partner organisations are experts in the use of genome editing, they are well-placed to play an important role in the development of such documentation perhaps by working with other scientific organisations or advising policymakers and government in order to do so.
- In Germany, participants felt that highlighting the regulatory European framework within which MDC (the ORION partner in Germany) operates could help to build public confidence.

¹⁸ https://www.theguardian.com/world/2019/dec/30/gene-editing-chinese-scientist-he-jiankui-jailed-three-years

"The information we've been given in this is pretty good. I don't think that's difficult information to get out there to people. What the possibilities are. What the reasons for it are. What the possible outcomes are. Who would have access to it?"

Event 2, Cambridge, UK

In Sweden and the UK, there was some confusion over the difference between the terms 'genome editing' and 'genetically modified', typically when participants were discussing the use of the technology on crops. However, once it was explained to participants that genetic modification involved introducing foreign genetic material from another organism while genome editing involved editing genes that already exist in an organism, they quickly understood this distinction. In their public-facing outputs, ORION partners should make clear to the public what the difference between these two is. This will help to address fears about the use of the technology.

"I thought I had been against GM foods. It has made me think differently about the possibilities now...I thought with foods and messing about with stuff is not good. Now I can see there is a lot of potential for better things."

Event 2, Cambridge, UK

There is a balance for the ORION partners to strike between providing enough detail about genome editing techniques, and not confusing the public with too much technical information, which could discourage people from engaging with the work scientists are doing.

- Participants in the UK and Czech Republic countries were particularly interested in understanding
 potential real-world applications of the technology and advised not to go into too much detail about
 how the technology works as people might lose interest if they cannot understand it.
- In Germany, participants felt that genome editing techniques are complex and could be intimidating for people to understand. It was not always immediately clear to participants why different applications and areas of research using genome editing (such as for medical purposes, on livestock, on plants) were important, so it is worth ORION partners clearly explaining why research is being conducted in these different areas.
- In contrast, in Sweden, participants were keener than in the other countries to understand details of the research processes and not just the end results or applications. They were also interested in understanding who was funding the research. It was felt they needed this nuanced information to be able to develop informed opinions about how genome editing is used.

Overall the ORION partners need to try to strike this balance by communicating about the research they are doing using genome editing technology and the outcomes they hope to achieve, but at least at first not going into too much technical detail. It may be a good idea for the ORION partners to position their work as exploring how life fundamentally works as this could help to pique the interest of members of the public – this was a finding from the UK events. The technical details of research could still be accessible via academic journal articles or similar, but ORION partners must acknowledge that much of the public would not be interested in

seeking out this information. If members of the public were interested in further detail, the ORION partners could signpost them to where they can find this information.

"I imagine the technicalities of it in terms of the specifics are probably not so necessary. Unless you're going to try it yourself, you don't need to know."

Event 2, Cambridge, UK

Another finding across the countries was the desire for **better education and information** to be presented using clear and accessible language, written in public-facing layman's terms. For example, in practice this could mean substituting terms like 'somatic' and 'germline' for 'non-heritable' and 'heritable' in communications.

"The most important information is surely education, because I think that the population knows too little. When I as an "amateur" know more, I can ask more detailed questions."

Event 2, Berlin, Germany

It was clear from the dialogue events in Germany and the UK that it is not only important for scientists to communicate about genome editing technology itself, but it is just as important for scientists to communicate about their underlying values and motivations for using the technology. This could help to build trust between the public and scientists, and people may become more open to learning about scientists' research using genome editing technology. Findings from the dialogue events show some particularly good potential ways for scientists to be able to do this, which are explored further in the next section:

- Show scientists speaking directly to the public about their own work (and provide them with the tools and resource to be able to do this).
- Have a two-way communication strategy between the public and scientists being able to ask questions and receive responses was highly valued by participants in the dialogue events.

"It is important to know their values because this builds trust. To create trust is important, more so than turning people into experts."

Event 2, Berlin, Germany

Participants wanted engagement methods about the technology to reach as many people as possible, therefore they suggested using online and televised approaches

Across the four countries, participants enjoyed participating in the public dialogue events, because it gave them the opportunity to talk to scientists, and have their opinions heard and questions answered. They greatly valued this two-way method of engagement. However, across all of the countries participants also recognised that this method has limitations in the number of people it could reach.

"I think this is a more valuable experience for us and for your guys as well. It is a complex topic and we have broad spectrum of people some with no scientific background you need to be educated about it and then talk about the ethical thing. It is quite valuable to do it in this way." Event 2, Cambridge, UK

"By being able to engage, you can get more information. You also have the feeling that you are a part of it."

Event 2, Berlin, Germany

Across all the countries, participants saw the need for ORION partners to communicate with as many people as possible about genome editing technology. This was because the technology was considered to have potentially big impacts on society. Most participants at the beginning of the events did not know about the technology or its associated ethical issues in any of the countries, and it is likely that the public at large across these countries do not either.

• For this reason, participants in Germany and the UK thought that children should be taught about it in school. The ORION partners such as the Babraham Institute in the UK already do educational outreach work within schools and in light of this it may be beneficial to increase this work further if possible.

"I would have put education in schools at the top."

Event 2, Cambridge, UK

 Having learnt about genome editing technology and its associated ethical implications, participants in Sweden expressed surprise that they had not seen these issues being discussed through popular media channels.

During the second event within each of the countries, participants were shown examples of methods of communication and engagement between scientists and the public.¹⁹ Because of the prevailing view that as many people as possible should learn about genome editing technology, in each country **participants felt that multiple methods of communication should be harnessed** by the ORION partners.

"It needs to be more than one type of media. There is no ideal communication platform, where you can reach everyone."

Event 2, Berlin, Germany

- In the UK, a 'building-block' approach to engagement was suggested where engagement methods with a wide reach are initially used to pique people's interest, who may then seek out more in-depth information about the technology in other ways.
- A similar approach was suggested in Germany, where it was suggested the MDC website could be a foundation for a communications strategy and provide links to a range of communication channels.

There was a particularly strong preference in all four countries for two methods of communicating with the public that have a wide reach: TV and social media. The ORION partners should be maximising the use of their

¹⁹ Methods discussed were as follows: animated videos, videos of scientists talking about their work, television, academic journals, the Babraham Institute, CEITEC, MDC and VA websites, social media, Citizen science, citizen forums, printed media, Public Science festivals, exhibitions showing the technology and open days and theatrical performances.

existing social media platforms and if possible, develop a strategy for televising their research. It was felt that these two methods in particular would enable the ORION partners to reach the most people.

"All the social media platforms have their pros and cons. Twitter is more about written communication, Instagram works a lot via hashtags. Facebook is a mixture. But generally it is a lot about visual content."

Event 2, Berlin, Germany

• In the Czech Republic, it was felt that of these two suggested approaches, the use of social media would be more appealing to younger members of the public and televised approaches may appeal more to older audiences. In Germany, participants also considered TV to be more popular among older groups.

In terms of content, videos of scientists talking about their work were rated highly by participants. It may be possible for ORION partners to film and publish videos of scientists on their websites, or perhaps there are opportunities to have scientists representing these organisations participate in broader documentaries about genome editing technology. Having scientists talking directly about their work makes it more transparent and accessible and could help to build trust with the public.

- In the UK, participants thought this information would be better coming directly from scientists rather than a PR figure or a celebrity. At the same time, there was some concern in the UK dialogue not to over-burden scientists if they are required to perform public engagement activities.
- The exception to the above point is if information comes from a well-known and trusted figure who is also an expert in that field; this was a suggestion from a Swedish participant. In Sweden it was suggested that scientists may need training on how to engage effectively with the public, as this is likely not their area of expertise. It may be possible to train members of staff within each ORION partner institute to act as ambassadors for their institute and act as a point of contact for the public regarding genome editing research.

"Your knowledge [the experts] makes it comfortable for us. I think that is incredibly powerful. If a polished celebrity was to talk, then it wouldn't come across as well."

Event 2, Cambridge, UK

"You would almost need a cult figure or advocate, along the lines of Hans Rosling, who knows what life is all about. Not a purchased PR person."

Event 2, Stockholm, Sweden

Animated videos were also rated highly by participants across all the countries, as they were viewed as being highly accessible and able to communicate information quickly – which was viewed as a benefit when communicating about a technology as complex as genome editing. However there was also recognition that it is difficult to convey lots of complex information about the technology or its associated ethical issues in a short, animated video. Participants in each country were shown an animated video from the Royal Society during the

dialogue events.²⁰ The perceived downside of this type of video content is that it does not allow for a two-way conversation between the public and scientists in the same way that the public dialogue events did. Another perceived downside of creating video content is that it could be potentially expensive and time-consuming to create.

"I'd definitely click on some interesting video sent to me. Those spread among people awfully fast."

Event 2, Prague, Czech Republic

- YouTube is a widely used public platform, and some participants in the German events mentioned that they had used popular YouTube channels to learn about science. It may be possible for the ORION partners to use their own YouTube channels, or link in with other popular scientific YouTube channels, to engage the public about their research.
- In the Czech Republic, while animated videos were liked by participants, some felt they could be child-focused and overly simplistic.
- Participants in the Swedish events perhaps criticised the animated video they were shown for being too positive about genome editing technology and not nuanced enough. For this reason, they felt animated videos could be too simple to the point of being unbalanced.

The ORION partners should at first communicate the types of information requested by the participants in these dialogue events through communication channels that the public most widely use. In addition to TV and social media, advertisements in public spaces, and events about science open to the public were viewed as valuable starting points across the countries. In each country, participants saw value in other methods of engagement as well and weighed up the pros and cons of each. For example, a traditional method of communicating scientific findings, via academic journals, was viewed as valuable to the scientific community but not accessible to the public. Below are some country-specific views and suggestions about methods of public engagement:

- In the UK, there was a suggestion that scientists could place photos of themselves and their contact details on any online articles they had written about genome editing. This would help to build trust and enable the two-way method of engagement participants valued at the public dialogue events.
- Open Days and Citizen science piqued an interest in participants at the German events because they
 presented opportunities for increased engagement with scientists. The perceived limitation of these types
 of methods was that they tend to be used by people who already have some interest and knowledge in
 the subject matter.
- Participants in the Czech Republic suggested various novel methods for educating the public about genome editing, including; showing videos about genome editing technology in the waiting rooms of

-

²⁰ <u>https://www.youtube.com/watch?v=XPDb8tqgfjY</u>

healthcare providers or on public transport; incorporating it into TV shows such as quizzes or dramas; developing board games based around genome editing; and reading about it in news or lifestyle magazines.

• In Sweden, participants were particularly critical of using printed media to engage with the public about genome editing technology, as it was viewed as being outdated and obsolete. Whereas in the other three countries, participants could still see some benefits to using printed media as a method of communication, even if they considered it old-fashioned (as was mentioned in the UK) or on the decline (as mentioned in the Czech Republic).

The art piece was successful at provoking discussion around the issues arising from a potential future use of genome editing technology, but was more successful in doing this when additional information was provided about it

The ORION consortium wanted to incorporate a piece of art into this public dialogue as a different mean of encouraging participants to discuss a potential future scenario arising from genome editing technology and to facilitate discussions around ethical implications of the technology. Accordingly, the ORION project launched a competition for commissioning this art piece in May 2018, which was managed by ORION partners in Berlin, the Max Delbrück Center for Molecular Medicine (MDC). Emilia Tikka, an artist, designer and PhD candidate at Aalto University, The School of Arts, Design and Architecture in Helsinki, won the bid with her work entitled 'Trajectories of longevity and CRISPR' (AEON)²¹. For this art piece, Emilia designed a speculative scenario of a rejuvenation technology embodied as a device for daily use and narrated as a fictional photographic story. Participants within each country were shown and/or told information about the artwork.

²¹ https://www.emiliatikka.com/new-page-1

Figure 4.1: Images of AEON Trajectories of longevity and CRISPR







Due to practical constraints, while the artwork was used in the public dialogue events within each of the four countries, it was presented in different ways, as follows:

- UK the artwork was physically present during the second event.
- Germany the artwork was physically present during the second event.
- Czech Republic it was not possible to show the physical artwork, so during the second event images of the artwork on Emilia Tikka's website were shown to participants, alongside a video of Emilia talking about the piece.
- Sweden the artist, Emilia, was able to attend the first event and give a brief introduction to the artwork in person. Then, the artwork was physically present for the second event and was re-introduced to participants. Prior to the events participants were invited to attend the unveiling of the artwork at the venue.

An aim of the art piece was to provoke discussion around the issues arising from a potential future use of genome editing technology. It successfully stimulated discussion about genome editing technology, sparked debate, and elicited an emotional response from participants. There were differences in how participants reacted to the art piece by country:

• In the UK, it was successful, to an extent, at provoking discussion as participants were able to talk about their reflections on the art. Participants reported it making them feel less optimistic about the technology than they had previously been, but they were also aware their views were being influenced by the choices of the artist such as the use of black and dark colours in the piece. They felt that if the artist had chosen to use bright colours or images of people smiling, it would completely change how it made them feel about the technology. Some participants in the UK were confused by the piece and mistook it to be a piece attempting to promote genome editing technology, albeit unsuccessfully.

"It is subject to the artist's interpretation and then your interpretation about his [sic] depiction."

Event 2, Cambridge, UK

"For me this is just a viewpoint but it's also a red line. It's about age. It wouldn't be something that I would be promoting."

Event 2, Cambridge, UK

• The art piece successfully provoked debate in Germany and raised many questions among participants. It led participants to choose sides: would they have been an opponent or proponent of using the technology in this way? It made participants who were previously positive about the technology uncomfortable. Like in the UK, German participants recognised the piece reflected the artist's interpretation but there was also a perception that portraying the technology in a more positive light would not have provoked discussion or led to more nuanced views.

"From our reaction you can see that it provokes people to think. Through art you have the opportunity that people engage with a topic. Everyone can take from it, what they want." Event 2, Berlin, Germany

• The art piece successfully provoked a heated discussion and emotional responses in the Czech Republic. The majority of participants rejected the idea of using genome editing technology to prolong ageing as they thought this could cause societal problems, especially if some people in society age at a normal rate while others do not age.

"This would raise so many ethical issues. This won't affect just the individual involved but their whole community."

Event 2, Prague, Czech Republic

• In Sweden, the art piece was very successful at stimulating discussion and drawing out emotional responses from participants. Even when participants stated that it was not helpful in stimulating discussion, this very statement ironically led to a discussion around genome editing. Some participants felt the art piece was boring and said they would have preferred an interactive piece or something that provided backstory. Participants in Sweden recognised that different people like to take in information in different ways, so art pieces like this can be useful ways to engage the public. At the same time, they felt it is difficult for a piece of art like this to convey lots of information about a specific topic in a clear and balanced way.

The artwork seemed to stimulate more discussion where there was more information provided about it, such as in the Czech Republic where participants saw a video of the artist talking about the work and the piece inspired heated debate, and in Sweden where the artist spoke to participants about the art piece. Without the additional information it could be more confusing or unclear for people what it was depicting (such as in the UK where some mistook it for a promotional piece). Therefore, this engagement method benefits from explanatory, supplementary information being presented alongside the art itself.

Across the countries, participants liked the concept of using art like this piece to communicate issues as it made them think and feel differently about the issues they had been discussing. In the UK and Czech Republic there were also concerns that this medium would only particular segments of society; many people do not visit art galleries, so would not experience this type of art.

"A very particular type of person goes to an exhibition. I don't know if it would effectively communicate to everybody."

Event 2, Cambridge, UK

A suggestion from the Swedish participants was to display this artwork in several different prominent public spaces in order to maximise its audience. Participants across different countries felt that genome editing technology and the ethical issues around its use should be taught to children in schools; this type of artwork could be an effective way of teaching and engaging young people in a school setting.

"Bring out the exhibition that so that people actually see it. You should be able to take it round libraries and cultural centers."

Event 2, Stockholm, Sweden

Overall, art work can be effective at stimulating discussion and communicating ethical issues however it should be presented alongside other information about genome editing. Doing this would maximise the audiences' understanding of the topic enabling participants to developed more informed views.

5 Conclusions & Recommendations

In this chapter, we firstly summarise the key differences in findings between countries that have been discussed in detail throughout this report. Then, we outline our overall conclusions and recommendations drawn from similarities across the countries.

The table below summarises country-specific differences for the themes covered in each chapter of this report, namely:

- views of the key challenges facing society, solutions to these and participants' starting points about genome editing;
- views of genome editing techniques (current and future); and,
- views of communication and engagement about genome editing.

These three sections are colour coded in the table below for clarity, with each colour representing a different section.

Table 5.1: Table of key differences by country

Theme:	Country:	Key differences:	
Views of the key challenges facing society, solutions to these, and participants' starting points around genome editing	UK	Challenges mentioned specifically in this country: A unique challenge raised in the UK was Brexit and the rise of populism/identity politics. Solutions mentioned specifically in this country: To tackle climate change, a specific solution suggested was lab-grown meat. Improved access to healthcare via technology. Participants' starting points around genome editing: Initial concern that scientists may not use the technology responsibly.	
	Germany	Challenges mentioned specifically in this country: Access to healthcare within a system of public/private health insurance, and the power of pharmaceutical companies. Unknown impact and perceived lack of regulation of genetically modified crops. Solutions mentioned specifically in this country: Technology to assist in early diagnosis and optimising treatments. Participants' starting points around genome editing: Initial optimism about medical benefits but concern that only the wealthy will be able to access it and around it being used for non-medical purposes.	
	Czech Republic	Challenges mentioned specifically in this country: Poor quality foods and the replacement of natural ingredients. Globalisation, the power of global corporations and non-democratic states. Solutions mentioned specifically in this country: Global sharing of information and joint scientific practices was seen as a general solution. Participants' starting points around genome editing: Initial thoughts that it could be used it agriculture, but concerns about it being exploited by special-interest groups or non-democratic states.	
	Sweden	Challenges mentioned specifically in this country: The spread and control of pandemics. Digital security of personal data. Solutions mentioned specifically in this country: A need to fund research was seen as a general solution. Participants' starting points around genome editing: Initial views that there needs to be improved education among the public r.e. genome editing technology (and its distinction to genetic modification), and a discussion around the current technical limitations of the technology.	

Views of genome editing techniques (current and future)	UK	Current uses: Participants struggled to understand the case studies presented and the link to practical applications. Sentiment that a lot more research needs to be performed before this technology can be used in an applied way, and it is reassuring that these techniques are being widely used in UK laboratories. Future uses: Participants discussed various benefits and concerns of each of the potential future applications presented to them, but these were not UK specific and were also raised in the other countries.
	Germany	Current uses: Participants expressed surprise that the technology was already this advanced, and concerns raised about interference with ecosystems, the influence of research funders, and ensuring equal access to the applications of the technology. Future uses: Germline genome editing for medical purposes initially viewed as more efficient than somatic genome editing, but after a discussion of the consequences of germline genome editing, participants felt the latter is currently more applicable, as it was seen as more controllable – unintended effects will be limited in being passed on.
	Czech Republic	Current uses: Particularly strong support for basic research and the research process, even where this does not lead to applied outcomes. Participants were more comfortable with the technology benefiting only a minority at first, assuming that its applications are eventually more accessible to a wider group. Concern was expressed however around misuse of the technology exacerbating inequalities. Some enthusiasm for the case study about applying genome editing to plants. Future uses: There was positivity about genome-edited crops being resilient to droughts caused by climate change, but this was not seen as important as medical applications for the technology. Participants disliked the idea of genome editing technology being used to enhance traits in humans and this reduced participants' previous general enthusiasm about the technology.
	Sweden	Current uses: Concern around who funds research and whether or not it is always a good use of money. There was also concern that only wealthy countries would have access to the technology and around potential issues with protecting individuals' data. Neutral about their case study applying genome editing to plants due to concerns of knock-on impacts on nature. Future uses: There were concerns about the uncertainties of somatic genome editing for medical purposes, around whether the genetic changes definitely would not be passed on. Participants liked the idea of genome editing being used to make crops more nutritious but had concerns over the safety of eating genome-edited crops and how these foods would be labelled. There were serious concerns around germline genome editing and editing human traits, with some participants suggesting this should be banned outright.

Views on communication and engagement	UK	What should organisations like the ORION partners be saying about genome editing: Participants thought there was value in scientists communicating where they had not succeeded or where there were difficulties in using the technology. A key finding from the UK public dialogue was the need for there to be some form of internationally agreed and respected public-facing documentation which outlines the current state and possible future applications arising from the use of genome editing technology (referred to as a 'roadmap' in the UK country report). What methods of engagement should organisations like ORION use: A 'building-block' approach to engagement was suggested where engagement methods with a wide reach are initially used to pique people's interest, who may then seek out more in-depth information about the technology in other ways. Participants felt information should come directly from scientists rather than a PR spokesperson or celebrity, and at the same time there were concerns that scientists could be overburdened with requirements to engage with the public. There was a suggestion that scientists could place photos of themselves and their contact details on online articles they had written to encourage two-way engagement. Views of the art piece: The art made participants feel negatively about the technology, but they acknowledged this was related to the artist's interpretation. Some participants were confused by the art and mistook it as a promotional piece for the technology.
	Germany	What should organisations like the ORION partners be saying about genome editing: Participants suggested that scientists communicate about both the potential positive and negative implications of genome editing technology, and clearly explain why conducting research about different applications of the technology (e.g. medical applications, using plants, with animals) is important. They also felt it was important to highlight the European regulatory framework that their ORION partner organisation operates within. What methods of engagement should organisations like ORION use: Participants suggested the ORION partner website could act as a foundation for other engagement methods. Open Days and Citizen science piqued interest in participants at the German events because they presented opportunities for two-way engagement. Views of the art piece: Participants in Germany chose sides, whether they would be an opponent or proponent of the technology being used in this way. Participants felt that if the art had been presented in a more positive way, it might not have led to a nuanced discussion.

Czech Republic	What should organisations like the ORION partners be saying about genome editing: Participants thought that scientists should focus on outlining the current and potential benefits of the technology, using real-world applications where possible. What methods of engagement should organisations like ORION use: Participants felt that TV would appeal more to older groups and social media to younger groups to communicate about genome editing. They suggested various novel methods of engagement about genome editing, e.g. incorporating it into TV quizzes or dramas and developing board games based around genome editing. Views of the art piece: The piece led to heated discussion, though some participants were unsure of the relationship between the two characters depicted.
Sweden	What should organisations like the ORION partners be saying about genome editing: Much of the discussion in Sweden focused around potential risks associated with genome editing technology. Unlike the other countries, participants in Sweden were more interested in understanding details about the research process and not just the end results or applications. What methods of engagement should organisations like ORION use: Participants were surprised they had not heard about genome editing/ethical issues related to the technology through popular media channels and suggested these should be used to reach the public. A finding from Sweden is that scientists may need training to engage with the public. Swedish participants were particularly critical of printed media as an engagement method. Views of the art piece: Even where participants felt the art did not help to provoke discussion, this ironically led to a discussion about the issues depicted. Some participants would have preferred an interactive piece with more backstory provided. There were suggestions for artwork like this to be displayed prominently in public spaces.

While there were some differences in the findings by country, as outlined in the table above and throughout this report, overall many of the findings were reported across countries. The table below outlines our conclusions drawn from the public dialogue events across all four countries and makes recommendations for the ORION partners based on these conclusions. **These are based on similarities in the findings across countries**. Specific conclusions and recommendations for each country can be found in the individual country reports.

Table 5.2: Table of overall conclusions & recommendations across countries

Conclusions	Recommendations	Recommendation for:
Participants were unaware of genome editing technology.	Communicate with the public about what genome editing is and how it can be used, including both the possible benefits and possible risks. This should be done in an authentic and honest way that explains where the technology is at now whilst managing expectations of what the future could bring.	 Scientists – the public trust scientists, so they will be important for raising awareness of the technology Communication and engagement specialists – need to effectively communicate with public about the technology
Once people understood the technology, they were very keen for there to be protections in place and strict regulation to prevent misuse. ORION partner organisations should actively support a fair and safe use of the technology. The public did not necessarily see it as the ORION partnership's responsibility to ensure the technology was used ethically outside of the partner organisations but more that they should be actively supportive of the idea of fair, safe use.	Participate in shaping the regulations of genome editing, for example by advising policy makers. ORION partners should promote and assist the development of internationally agreed documentation that states what is and is not allowed regarding genome editing technology. The public and advocacy groups may also need to be involved in the development of this.	 Communication and engagement specialists – should communicate about the ORION partners' stance on ethical use of the technology Policy makers should reach out to ORION organisations' scientists for guiding use of the technology and to outline ethical regulations

Participants did support life sciences and biomedicine fundamental basic research, even if it does not necessarily lead to applied outcomes. They saw this as an important part of the scientific process.

Frame research as being exploratory, highlighting the importance of developing a learning of how biological processes work in order to increase our understanding about life. This will help the public to understand the value of basic research.

- Scientists explain rationale and moral behind their basic research to gain further public's support; it is important to community 'why' research is being conducted as well as 'how'
- Communication and
 engagement specialists —
 provide the tools and
 support needed for scientists
 to be able to communicate
 about their research
 effectively

Participants were most accepting of the use of somatic editing for medical purposes when considering future possibilities of genome editing. Participants found somatic genome editing most acceptable when it was to tackle serious or lifethreatening disease, and only if it has been proven to be safe.

They saw potential value in genome editing crops and animals, but this was less of a priority than medical applications of the technology. Their biggest worry was the use of germline editing and editing human traits due to the possible ethical implications on society and unknown/unintentional consequences.

Communicate safety/risk implications of research to the public. Further research needs to be conducted using genome editing technology before it can be used in applied settings to ensure it is safe.

Demonstrate you are conducting research using somatic editing for medical purposes if possible, as this area of research was most valued by participants across the four countries.

Show appreciation of ethical challenges surrounding germline editing and object to attempts to use the technology to enhance human traits.

- Scientists it is important for them to know what the public think is acceptable using genome editing technology and what isn't acceptable
- Management within ORION
 partners should guide the
 type of research being
 conducted in the institutions
 to ensure it remains ethical
 and in-line with the public's
 priorities

When it comes to communicating with the public about genome editing technology, participants felt that as many people should learn about it as possible due to its potential impacts.

Participants therefore valued methods of communication they were already using (TV, online) as these have the widest reach.

Maximise ORION's online presence such as its social media channels and use accessible videos where possible, as this strategy could have the widest reach. Also explore the possibility of televising research and findings. If this is not feasible due to resource implications, it may be possible instead to link in with existing documentaries or popular science channels either online or on TV.

 Communication and engagement specialists – it is important to know, and use, the best ways to engage public

There needs to be a balance between providing enough information whilst not overwhelming people with too much technical detail, which could cause them to disengage.

Provide a story of why research is being carried out, what it hopes to achieve and the value it hopes to bring, as it is important for the public to understand the motivation and values behind scientists' work. Ensure that public-facing information uses layman's terminology, for example using terms like 'heritable' as opposed to 'somatic', so that the research is accessible for as many people as possible.

- Communication and engagement specialists need to effectively communicate with public about the technology
- Scientists when presenting their research or findings to the public, scientists should try to minimise jargon and complexity

Participants seemed to enjoy participating in the dialogue events as they were able to interact directly with experts and hear responses to their questions.

Find opportunities for a two-way method of engagement between the public and scientists, alongside methods of communication such as online videos or social media. This could involve running open-days or other events where members of the public can meet scientists, or online interaction such as including the contact details of scientists at the top of articles they publish about their research.

- Communication and engagement specialists try and use methods of engagement with the public that allow for a discourse between scientists and the public
- Scientists be open to interacting with the public about the research

Participants supported the idea of scientists talking about their own work as it aids transparency.

Engage with the public about the work of scientists. Scientists should be able to talk to the public directly about their own work and about both when their research has been successful and less successful (or, where it has met or not met their expectations). Hearing this from scientists directly rather than a celebrity or PR professional increases public trust.

- Scientists scientists are deemed as trustworthy; the public will take more note if information comes from them. Communicate about values and motivations behind the research
- Communication and engagement specialists should make use of scientists when considering communication methods, as this could increase trustworthiness of communication
- Management within ORION partners engaging with the public may be outside of scientists' expertise. There should be training to explain how to do this, and how to do it in a way which does not overburden scientists.

The art piece was an effective way of sparking debate or getting people to think about issues in a different way. It was successful in this case where lots of additional information was presented alongside it. Participants thought that this mode of engagement will not appeal to all parts of society.

Incorporate artwork into engagement methods when communicating about genome editing technology, but if used, this should be alongside other engagement methods to ensure the technology is presented in a balanced way. Artwork could be used for example in schools and education as way to engage children.

Communication and
 engagement specialists —
 different methods of
 communication will be
 more/less effective for
 different parts of society, so
 a mix of different methods
 should be used

Regulation

and

protection of

the tech was

a priority

is an important

Figure 5.2: Diagram of conclusions & recommendations

Communicate about what GE is as well as the possible benefits and risks in the most transparent way possible, managing expectations



Participate in shaping and supporting regulation, despite not being responsible for ethical use of tech outside of ORION



Frame basic research as being exploratory and explain the importance of it





Communicate about risks and show

appreciation of ethical challenges. People are

worried about unknown effects: more research

needed to test safety. If possible, show you are

conducting research using somatic genome

editing for medical purposes

People were unaware of genome editing technology

Art can be an effective way of sparking debate


Conclusions drawn from public dialogue events

= recommendations for ORION partnership

Scientists







Management

Somatic editing for medical purposes is most accepted, germline editing of human traits was not acceptable

Preferred methods of communication are wide reaching such as TV or online Incorporate artwork, alongside other methods, to present the technology in a new way – e.g. in schools

Participants support idea of scientists talking about their findings Engage directly
with the public. Talk about
both success and less
successful stories, and
about their driving values
and motives

There is also need for 2-way engagement

balance between providing information but not Find ways for interactive engagement, not just 1-way communication

Provide a story of why research is being conducted is important – public facing info should use layman's terms

Maximise online presence and consider ways to incorporate video content in engagement strategy

Appendix A: Case studies shown to participants

UK case studies:

Editing model organisms

Babraham scientists discovered an important biological "switch" in the 1980s.

This switch is made from the 'PI3K' family of proteins. These <u>proteins control</u> how cells grow, how cells reproduce, what jobs are done by cells, and even how long cells live for. These are important factors for our <u>health and maintaining our health as we age</u>.

Using GE techniques, scientists are also looking to identify more proteins that help control this switch.

If scientists found a new protein involved, they could use genome editing to edit its DNA in mice so that it no longer worked.

By looking at the <u>effect this has on mice</u> they could learn the role this new protein plays in controlling the PI3K switch.



Ipsos MORI Social Research Institute

Epigenetic marks

Scientists now know that the way our <u>genes work can be affected by factors in the environment such as chemical 'marks</u>' that get stuck onto DNA throughout our lives – as well as the DNA sequence itself. These <u>'epigenetic' marks</u> help determine which parts of the DNA code can be read.

BI scientists study how <u>epigenetic marks in a mother's egg cells</u> can affect <u>how the DNA is used in her children's cells</u>.

Using GE techniques, they hope to be able to understand how changes such as the <u>mother's</u> <u>age and diet can affect the epigenetic marks</u>, and if these changes can be passed on to offspring.

If scientists found epigenetic marks that controlled a gene involved in disease, they could use CRISPR to edit the epigenome and change these marks. They could <u>switch off genes that cause disease</u>, or <u>switch on genes that prevent disease</u>. These changes could potentially be <u>passed on to offspring</u>.



Ipsos MORI Social Research Institute

How the immune system works

The cells of our <u>immune system produce antibodies</u> to defend us from bacteria and viruses.

As we age, the number of different antibodies we can produce starts to decrease, and our <u>immune system stops working as effectively</u>.

Using CRISPR/Cas9 BI scientists study what <u>causes our immune system to decline as we age</u>: why do we produce fewer antibodies; why does our immune system not respond as well as when we are young, and why do vaccines not work as well?

If scientists found that they could use <u>CRISPR</u> to edit the human genome and <u>reverse</u> this age related decline, then they could <u>improve the immune systems of older people</u> and stop them from getting so many diseases.



Ipsos MORI Social Research Institute

Germany case studies:

Converting skin cells into egg cells

The northern white rhino is as good as extinct, as the species only has two remaining females, and they are directly (genetically) related.

As numbers declined, researchers began collecting and deep-freezing tissue samples (skin cells), and (sperm cells) from northern white rhinos.

Turning a piece of skin into a living rhinoceros would be a truly remarkable feat of cell engineering – one that still requires a great deal of research.

MDC has achieved the first step, using tissue taken from a different rhino species, to convert skin cells into stem cells.

The next steps for MDC have never been done with the rhino species: stem cells \rightarrow germ cells \rightarrow egg cells.

This process has been done before in mice, although it took many, many years.



Ipsos MORI Social Research Institute

How does titin affect heart growth

Scientists edited the titin gene in mice in different ways and looked at the effect this had on the mice.

They found that one change in titin caused the mice to have bigger hearts, and a different change in the same gene caused the mice to have smaller hearts.

The scientists hope that in future, knowing which changes cause which effects will help doctors diagnose people better, and could lead to personalised treatments for patients.

Once we understand what changes cause what effects, a possible treatment could involve using genome editing to correct these specific changes.



Ipsos MORI
Social Research Institute

Understanding gene expression

One sign of kidney disease is 'albuminuria'. This is when proteins leak out of your kidneys into your urine.

Scientist know that there is an area of the genome associated with albuminuria. This area contains many different genes and MDC researchers wanted to find out which one is responsible for causing the disease.

Using rats and zebrafish scientists found one gene that was important. When they turned off the gene, using CRISPR, the zebrafish leaked a florescent green molecule out of their kidneys, showing that this gene was the cause of the leaky kidneys.

Working with other scientists, they showed that this same gene is changed in some human patients.

Now scientists know that the same thing happens in humans and zebrafish, they can use zebrafish to understand how turning off this gene causes leaky kidneys.



Editing model organisms

Brain tumours like glioblastoma multiforme (GBM) are one of the most aggressive forms of cancer, and very difficult to treat.

MDC researchers are using CRISPR-Cas9 to re-create human cancers in mice in the hope of finding new medical therapies. They insert tumour cells into mice and let them grow.

The mice are then humanely killed and researchers are able to look at the cells in the tumour, and how the cancer has responded to a certain therapy.

They are looking at how the tumour cells have grown and whether the cancer cells develop resistance to certain therapies.

By doing this they hope to understand how and why some cancers stop responding to chemotherapy, and find new ways of testing whether human patients will respond to a specific type of chemotherapy.



Ipsos MORI
Social Research Institute

Czech Republic case studies:

Re-programming immune system cells

Cancers are caused by 'glitches' in a cell's DNA that change the genetic instructions that allow us to grow and develop healthily.

There is always more than one DNA glitch needed to cause cancer. The combination of different glitches varies between patients – each cancer is unique.

CEITEC researchers are trying to develop a new treatment for cancers such as leukaemias and lymphomas, called CAR-T therapy.

Healthy immune system cells are taken from a patient's blood. They are edited using CRISPR to recognise the specific combination of changes in that patient's cancer.

The cells are then put back into the patient in order to target that patient's cancer.

This research involves the use of mice that have purposely been given cancer.



Understanding how plant molecules work

The two molecules that scientists use most often to edit the genome are <u>CRISPR</u> and Cas9.

These molecules occur naturally in plants and are used by the plants' immune systems to stop them getting diseases.

Scientists can put these molecules into other types of cells (humans, animals, other plants) and use them as a tool to edit the genome. They act like a pair of molecular scissors!

Plant scientists at CEITEC study how CRISPR and molecules similar to Cas9 are involved in plant's immune systems.

They look very closely at the molecules and try to understand how they work.



Ipsos MORI Social Research Institute

Understanding how viruses work

Bacteria are tiny living organisms that can survive on their own or inside a host such as a human. They can be harmful or helpful to other organisms.

Viruses are also tiny living organisms, even smaller than bacteria that can only survive by invading the cells of a host.

Some viruses don't infect humans, animals or plants, but can actually infect bacteria, and can harm or even kill bacteria!

Scientists at CEITEC are studying how these bacteria-infecting viruses work, and how they invade bacteria cells.

One day, scientists could potentially use genome editing to alter the genomes of these bacteria-infecting viruses.

They could programme them to kill bacteria that are dangerous to humans, or kill bacteria that have developed antibiotic resistance.

ipsos

סטטמו ועבאבמוכוו ווואנונענפ

Swedish case studies:

Genome edited potatoes

Plants, including potatoes have traditionally <u>been genetically modified by</u> <u>selective breeding</u> to give desired traits both in terms of taste and crop yield.

Genome editing provides a faster way to edit crops to <u>study them</u> or <u>improve</u> <u>them</u> by making them more nutritious or resistant to pests and extreme weather.

Scientists have <u>successfully tried CRISPR</u> on potatoes after previous technologies introduced too many genetic errors.

Genome editing has now been successfully implemented in potatoes, producing new starch qualities for improved usability in food, such as a low-GI potato i.e. a potato with reduced sugar content.



Ipsos MORI Social Research Institute

Genome editing bacteria to produce biofuels

Genome editing can be used to produce biofuels. A biofuel is made from biomass, i.e. plant or algae material or animal waste.

Plants and some bacteria can produce sugars from light and carbon dioxide using a <u>process called photosynthesis</u>.

These <u>sugars can be processed to produce biofuels</u>, but <u>what if the processing wasn't necessary</u>?

Scientists are working on genetically modifying bacteria to <u>directly produce</u> <u>biofuels from only light and carbon dioxide</u>.

This research aims to contribute to the future of fuel production.



Editing embryonic stem cells

Age-macular degeneration is the leading cause of severe, permanent vision loss in people over age 60. It happens when the small central portion of the eye's retina, called the macula, wears down.

A treatment for this disease could be to use <u>embryonic stem cells to replace the damaged cells in the eye</u>. These cells are taken from <u>undeveloped human</u> <u>embryos, mostly from IVF treatments</u>, and they have the ability to become any type of cell in the body.

Because the cells come from a <u>donor</u>, the <u>patients immune system would normally</u> <u>reject these cells</u>.

Scientists are using <u>CRISPR</u> to <u>produce stem cells that won't cause an immune reaction</u> and can therefore be used to treat macular degeneration.



Ipsos MORI Social Research Institute

Understanding how cells function

Genome editing can be used to speed up complex screening processes in research. For example, <u>a researcher might want to know what genes</u> contribute to a specific disease.

Using CRISPR and cells grown in the lab, it is <u>possible to edit many genes at</u> the same time, and then test what effects these edits have on the cells.

Scientists are developing a CRISPR screening platform that they can use to study diseases such as cancer and arthritis.

They are <u>interested in finding which genes cause disease when they are</u> changed, because it makes it easier to develop better drugs and treatments.



Appendix B: Future possibilities of genome editing handouts

Future possibility 1: Genome editing for medical purposes

- Some diseases are caused by, or are influenced by, genes.
- Genome editing has the **potential to treat disease** by editing out the 'faulty' gene.
- There are two possible types of genome editing in humans.
 - Heritable (germline) changing the genes passed on to children and future generations, by editing reproductive cells and early stage embryos (through sperm and eggs)
 - <u>Nonheritable</u> **(somatic)** editing faulty genes in a way that is not passed on through generations (not through sperm and eggs)





Ipsos MORI Social Research Institute

Future possibility 1: Genome editing human embryos

- Last year in China, a scientist edited human embryos to make them resistant to the HIV virus.
- The first genetically edited children were born in 2018 named Lulu and Nana. This is currently illegal in the UK.
- Editing the gene that HIV uses to infect a person's cells, may accidentally
 cause other 'side-effects' which could be harmful (such as a weaker
 immune system) or beneficial (such as increased intelligence) we cannot
 predict with certainty.
- Because the embryo was edited, the changes made could be passed on to the twin's descendants and their descendants and so on.
- Scientists heavily criticised this work, which was conducted poorly. It could be possible to bypass issues this raised by being more careful, or by only using somatic genome editing.



Future possibility 2: Changing traits in humans



- In the far future, it may be possible to use genome editing technology to change or **enhance traits** in humans like eyesight, strength or endurance
- Allow parents to choose their offspring hair colour, eye colour and some even think intelligence
- Or increase **human strength or endurance**, thus creating super athletes or humans who can survive for longer in extreme and hazardous working environments like deep-underwater, or space
- Some predict it may even be possible to **slow down ageing**





Ipsos MORI Social Research Institute

Future possibility 3: Genome editing animals

GE could result in... healthier animals and contracting fewer diseases



- For example, chickens could be made resistant to bird flu, but the edits may have other effects on the cells of the chickens
- Or more environmentally sustainable farming
 - Animals may need less space, or require less feed if they are more resilient, but some worry this could negatively affect animal welfare



- GE animals could bring about medical benefits:
 - GE mosquitos could be prevented from carrying diseases like malaria, but some worry about effect of releasing GE animals into 'natural' populations.
 - GE pig organs will be used in human transplants in the next five years to help rejection by our antibodies / immune system to a foreign tissue



Future possibility 4: Genome editing plants & crops

- GE could possibly be used to edit the genes of crops, to **improve** taste, shelf-life, resistance to disease.
 - Some people get sick when they eat food with gluten in, like wheat. Wheat could be genome edited to be gluten-free
 - GE bananas could be more <u>resistant to a damaging fungus</u>
 - GE pineapples (pink-flesh) or tomatoes (purple skin) have health benefits e.g. higher concentration of antioxidants. Where do we draw the line with cosmetic vs health benefits?
- With climate change, GE plants or crops might cope better with rising temperatures or could survive in flood water









Appendix C: Information shown about the art piece

Emilia Tikka constructs a possible future for humanity in which aging is a choice. A scientific paper reported that cells become "rejuvenated" when four genes are partially activated. In mice, this even led to longer life spans.

What would it be like if humans could regulate their own genes with high precision and reverse the aging process?

"I imagine someone would have to inhale the mixture from the vials – including CRISPR-Cas9 – on a daily basis to stay young"

They show a couple: The man has been preserving his youth for decades, while the woman has let nature take its course.

Appendix D: Glossary of Terms

Term	Definition	
CRISPR/Cas9 genome editing technique	A recently discovered genome editing technique adapted from a naturally occurring genome editing system in bacteria. This technique is cheaper, faster, more efficient and more versatile than preceding available techniques	
Designer babies	Children who have had their genome-edited for desirable traits, including removal of life-threatening genes/mutations and/or cosmetic changes such as changes to eye colour or height	
Epigenetics	The study of inherited traits caused by mechanisms other than changes in the underlying DNA sequence	
Gene	A section of DNA containing information to make proteins	
Genome	All of the genes in an organism's DNA	
Genome editing	The act of editing a gene/s within an organism's genome, which could be one specific gene or multiple genes at once	
Genome editing technique	One specific method of editing the genome, such as the CRISPR/Cas9 genome editing technique	
Genome editing technology	The entire suite of genome editing techniques that are available for scientists to use which give scientists the ability to change an organism's DNA	
Germline genome editing	Refers to editing the genomes of embryos, sperm and eggs, so that changes made would be inherited by future offspring	
Laddering effect	An effect whereby the acceptability of something (in this case genome editing technology) increases with greater usage, or it becomes more acceptable in different contexts with greater usage	

Off-target effects	Changes made unintentionally to DNA by genome editing, often due to the similarity of DNA sequences elsewhere in the genome
ORION	Open Responsible research and Innovation to further Outstanding kNowledge - a four-year project funded by the European Union's Horizon 2020 Research and Innovation Programme (agreement No. 741527) under the Science with and for Society (SwafS) Programme, to build effective cooperation between science and various sectors of society. A consortium of organisations conducting, funding and supporting research across Europe are participating in the project
Somatic genome editing	Refers to edits in cells other than embryos, sperm and eggs, so that changes made to the genome are not heritable.
Xenotransplantation	The act of transplanting tissues or organs between members of different species

Appendix E: Advisory Group members

International Advisory Group members

Name	Organisation	Role
Simon Burrall	Involve Foundation (UK)	Senior Associate
Marta Agostinho	EU-LIFE	Coordinator
Luca Franchini	Fondazione ANT (Assistenza Nazionale Tumori) Italia Onlus (Italy)	Psychologist (MSc. Social, Work and Communication Psychology)
Annette Leßmöllman	Faculty of Humanities and Social Science, Karlsruhe Institute of Technology, (Germany)	Vice-Dean
Michael Wakelam ²²	The Babraham Institute (UK)	Director
ORION staff leading this proje	ct at participating organisations me	mbers of the Advisory Group:
Nikola Kostlánová	Central European Institute for Technology, CEITEC (Czech Republic)	Scientific Secretary
Luiza Bengtsson	Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft, MDC (Germany)	Wissenstransfer and Outreach
Maria Hagardt	Vetenskap & Allmänhet, VA (Sweden)	International Relations & Communications Manager
Stephanie Norwood	The Babraham Institute (UK)	Public Engagement ORION Open Science Project Officer (maternity cover)

 $^{^{22}}$ Professor Wakelam sadly passed away on $31^{\rm st}$ March 2020, before the publication of this report.

Appendix F: Babraham Institute & Ipsos MORI

Project Team

The Babraham Institute Public Engagement Team

Name	Organisation	Role
Emma Martinez-Sanchez	The Babraham Institute	Public Engagement ORION Open Science Project Officer
Stephanie Norwood ²³	The Babraham Institute	Public Engagement ORION Open Science Project Officer (maternity cover)
Tacita Croucher	The Babraham Institute	Public Engagement Manager
Hayley McCulloch ²³	The Babraham Institute	Public Engagement and Knowledge Exchange Manager (maternity cover)

Ipsos MORI project team

Name	Organisation	Role
Michelle Mackie	Ipsos MORI	Research Director and Head of Ipsos Dialogue
Graham Bukowski ²³	Ipsos MORI	Associate Director
Sarah Castell	Ipsos MORI	Head of Futures
David Hills	Ipsos MORI	Senior Research Executive
Holly Kitson	Ipsos MORI	Senior Research Executive
Amber Parish	Ipsos MORI	Project Administrator

²³ These individuals left the Babraham Institute / Ipsos MORI prior to the reports being published

For more information

3 Thomas More Square
London

t· +44 (0)20 3059 5000

www.ipsos-mori.com http://twitter.com/lpsosMORI

About Ipsos MORI's Social Research Institute

The Social Research Institute works closely with national governments, local public services and the not-for-profit sector. Its c.200 research staff focus on public service and policy issues. Each has expertise in a particular part of the public sector, ensuring we have a detailed understanding of specific sectors and policy challenges. This, combined with our methods and communications expertise, helps ensure that our research makes a difference for decision makers and communities.